

|  |                  |   |
|--|------------------|---|
| <p><b>(51) International Patent Classification <sup>6</sup> :</b></p> <p><b>C12Q 1/68, C12P 19/34, C07H 21/02, 21/04</b></p> | <p><b>A1</b></p> | <p><b>(11) International Publication Number:</b> <b>WO 96/34984</b></p>       |
|  |                  | <p><b>(43) International Publication Date:</b> 7 November 1996 (07.11.96)</p> |

**Published**  
*With international search report.*

The invention is directed towards a method of amplifying target nucleic acids by using two oligonucleotide probe complement pairs. Each member of the probe pair contains a chemical functionality group which permits linkage of the probes when the functionality groups are adjacent to one another following hybridization of the probe pairs to the template. One probe in each pair is composed of two regions, a first region which hybridizes to the target and which contains the chemical functionality group and a second, protecting region which prevents target independent joining as shown in the figure. The other probe in the pair contains the corresponding chemical functionality group. Upon joining of a first probe pair, an amplification can proceed in which the newly joined first probe pair can serve as a template for the second, complementary probe pair, which can in turn serve as a template for unjoined first probe pairs. This cyclic amplification is sensitive enough for a discriminative amplification of sequences which differ by merely a point mutation and therefore is suitable for point mutation detection and genotype determination as well as for the determination of the presence or absence of a specific nucleic acid in a sample.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                           | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                                  | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                   | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                   | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                                  | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                                  | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                    | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                    | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                    | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                               | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                               | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                                | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                                  | SN | Senegal                  |
| CN | China                    | LT | Lithuania                                | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                               | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                   | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                   | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                      | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                               | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                     | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                                 | US | United States of America |
| FR | France                   | MR | Mauritania                               | UZ | Uzbekistan               |
| GA | Gabon                    |    |  | VN | Viet Nam                 |

5

## NUCLEIC ACID DETECTION AND AMPLIFICATION BY CHEMICAL LINKAGE OF OLIGONUCLEOTIDES

10

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to a non-enzymatic method and kit for amplifying and detecting existing target nucleic acid sequences in a test sample.

15

More particularly, the present invention concerns a method and kit for the detection of the presence of a certain sequence in a sample of genetic material. The method and kit of the present invention are highly sensitive to small alterations in an examined sequence, and thus are useful for detection of minute sequence alterations, such as, for example, point mutations, i.e., single base-pair alterations in a DNA sequence.

20

The present method and kit are also useful for identifying the presence of a foreign genetic sequence in a sample of genetic material, for example, for detecting the presence of specific bacterial or viral nucleotide sequences in plant and animal DNA. The method is entitled Chemical Amplification of Nucleic Acids and is abbreviated as ChANA.

25

In the last two decades an extremely large number of human genes have been isolated, fully sequenced and the genetic basis of many diseases such as, for example, Cystic Fibrosis, Hemophilia, Lesch-Nyhan syndrome,  $\beta$ -thalassemia, Sickle Cell Anemia, Phenylketonuria, Tay-Sachs, Gaucher, Duchen/Becker muscular dystrophy and many others have been elucidated. A large number of genetic diseases have been shown to be caused by multiple alternative sequence alterations such as a replacement (e.g., point mutation), or a deletion or insertion of known number of nucleotides, in the genes of different individuals. For example, 177 different point mutations and 66 different insertions and deletions in the CFTR gene have been identified as alternative genetic origins for this gene associated disease, Cystic Fibrosis (Darvasi, A. and Kerem, B. (1994) Short tandem repeats and mutations in the coding region of human genes. in press). As

35

40

a consequence of such point mutations or small sequence alterations, the protein encoded by such genes is not produced, prematurely truncated or is produced in a modified form which affects its function/s. Much evidence supports the idea that at least part of the variable penetrance, i.e., age of onset and severeness, characterizing some of the genetic diseases is due to the variability of sequence alterations in their associated genes. Furthermore, many cancers have been shown to be associated with somatic point mutations in certain genes.

It is now possible to obtain genetic material from an individual, amplify a certain gene region using the polymerase chain reaction (PCR) technology, and then identify, by DNA sequencing or by other mutation detection approaches, whether the individual has a mutation at any particular site in this region. Furthermore, it is also possible to determine the genotype of such individual, i.e., whether the individual is healthy, has a certain disease or whether the individual is a "carrier" i.e., is heterozygous for the mutation of the site tested. When such analyses are performed on fetal cells, it becomes possible to determine the probabilities that the fetus will bear a certain inherited disease. This may allow the treatment of the disease shortly after birth using special diets or medicines, or using genetic therapy, or, if treatment is not feasible, offers the option of terminating the pregnancy.

Such techniques have also become important in a number of other applications including in forensic medicine where typically only minute samples are available, in questions of paternity, and in the analysis of a sample for the presence of a nucleic acid of a specific pathogen, for example, nucleic acid of viral origin such as HIV.

As mentioned, many genetic diseases have multiple alternative genetic origins. Some of these diseases are fairly common in certain populations. For example:  $\beta$ -globin defective alleles, causing  $\beta$ -thalassemia, are widely spread in some Middle East populations; various defective CFTR alleles are carried in a heterozygous form by one of twenty individuals (5%) and the disease affects about 1/1600 individuals of Caucasian descent in the world (Harrison's Principles of Internal Medicine 9th Ed. Isselbacher, Adams, Braunwald, Petersdorf and Wilson Eds. McGraw-Hill Book company, N.Y., pp. 1233). Because of the high frequency of Cystic Fibrosis and other genetically inherited disorders there is a widely recognized need for, and it would be highly advantageous to have, a low cost method, demanding merely non skilled



personnel for its execution, that enables the efficient and accurate detection of DNA sequence alterations.

5 The most basic method for detection of point mutations is DNA sequencing, the most widely used sequencing method being based on the dideoxynucleotide chain termination procedure (See, Sanger F. (1981), Science 214, 1205-1210). The development of DNA and dideoxynucleotide conjugated fluorescent dyes, and suitable detection systems, enabled the improvement and the automatization of the basic dideoxy chain termination technique.

10 Other methods which have been used to determine the presence of alterations in known DNA sequences include allele specific oligonucleotide (ASO) hybridization; reverse-ASO; restriction site generating PCR (RG-PCR); denaturing/temperature gradient gel electrophoresis (D/TGGE); single-strand  
15 conformation polymorphism (SSCP); heteroduplex analysis; restriction fragment length polymorphism (RFLP); PCR restriction fragment length polymorphism (PCR-RFLP); nuclease protection assays; chemical cleavage and other, less frequently used, methods.

20 These methods, although of great scientific importance, suffer from drawbacks limiting their routine use since they lack one or more of the following aspects rendering a method applicable for wide screening of various DNA alterations in many individuals. These aspects include: (1) Highly skilled  
25 personnel are needed for (a) accurate execution of the procedures, many of which include several complicated steps, specially gel electrophoresis and/or complicated blotting and hybridization procedures, and (b) for interpreting the results; (2) Strict calibration steps are needed before the examination of any new DNA alteration; (3) Theoretically, some of the above mentioned procedures, are  
30 not suitable for the detection of all alterations; (4) Some are time and effort consuming regarding the procedures themselves and/or the interpretation of their results; (5) Some of the procedures, specially those involving gel electrophoresis, are not easy to automate; and above all, (6) these methods are  
35 all based upon the use of enzymes such as DNA- and RNA polymerases, restriction endonucleases single-strand-specific endo- and exonucleases and the like, which in addition to being expensive, exhibit lot-to-lot variations in activity and in the concentration of undesired nuclease contaminants. Such variations detract further from the reliability of these methods.

As mentioned, advances in the field of molecular biology over the last two decades have enabled the detection of specific nucleic acid sequences in test samples taken from a patient or other subject. Such test samples include serum, urine, feces, saliva, amniotic fluid, and other bodily fluids. Detection of specific  
5 nucleic acid sequences can be used to identify genetic disorders or diseases, as well as the presence of pathogenic bacterial and viral disease agents in humans and other species.

In many cases of interest, a desired nucleic acid sequence is present at a  
10 very low concentration in an examined sample. In such cases, unless assay sensitivity can be increased, the presence of the desired molecule may escape detection.

The standard method for amplifying and detecting target nucleic acid  
15 sequences is the polymerase chain reaction (PCR). (see Saiki *et al.* Science 239, 487 (1988) and Mullis *et al.* in U.S. Patent 4,683,195). A problem with PCR is non-specific polymerization leading to spurious background signals.

The PCR method is aimed at the amplification of a specific nucleic acid  
20 sequence. It enables a repeated replication of a desired specific nucleic acid sequence using two oligonucleotide primers complementary each to either strand of the sequence to be amplified. Extension products, to which these primers are incorporated, then become templates for subsequent replication steps. The method selectively increases the concentration of a desired nucleic acid sequence  
25 in a geometric rate even when that sequence is not purified prior to amplification, and is present only in a single copy in a particular sample. The PCR method may be used to amplify either single or double-stranded DNA or complementary DNA (cDNA).

30 PCR technology is useful in that it achieves a rapid and extensive amplification of a polynucleotide molecule. Nevertheless, two practical problems exist when the PCR method is applied for amplification of target nucleic acid sequences: (1) non-specific hybridization between extraneous sequences, in an examined nucleic acid, with the amplification primers may  
35 results in a co-amplification of irrelevant sequences. Furthermore, as the level of amplification increases, the quantity of such co-amplification products also increase; (2) because of the ability of PCR to readily generate millions of copies for each initial template, accidental introduction of the end product of a previous reaction into other samples easily leads to false-positive results.

The advent of PCR led to the development of additional amplification methods. One such alternative method is disclosed by Backman *et al.*, EP 320 308, known as the ligase chain reaction (LCR), for amplifying a target nucleic acid sequence. In LCR, four oligonucleotide probes are employed in excess. The first and third probes form a complementary oligonucleotide probe pair. The second and fourth probes form another complementary oligonucleotide probe pair. The first and second probes hybridize to sequences that are contiguous in the first strand of the target nucleic acid sequence. When hybridized, the first and second probes abut one another in a 5' phosphate - 3' hydroxyl relationship, so that a ligase can join the two probes into a fused product. Also, the third and fourth probes hybridize to sequences that are contiguous in the second strand of the target nucleic acid sequence. When hybridized, the third and fourth probes abut one another in a 5' phosphate - 3' hydroxyl relationship, so that a ligase can join the two probes into a second fused product.

The first and second fused products are separated from the target strands, in effect doubling the target population in the sample. The fused products then serve as templates for further LCR reactions by hybridizing to the complementary probes. As the cycle of hybridization, ligation and denaturation is repeated, the population of fused probes increases at a geometric rate. The fused probes are detected by standard methods.

These amplification reactions permit rapid analysis or characterization of sequences of interest, even where the starting amount of material is extremely small. However, it is important that the amplification process be highly specific, since the amplification of untargeted sequences along with the target signal impairs the reliability of the amplification process.

One problem associated with LCR is that, by definition, the procedure requires four oligonucleotide probes and a ligase, and may result in the non-specific "blunt-end ligation" of the oligonucleotide probes. Such non-specific "blunt-end ligation", should it occur, cause a target-independent geometric amplification of the fused products. This can lead to high background signal of false-positive results. These target-independent products are indistinguishable from the desired amplified target sequence.

Both PCR and LCR have an additional drawback due to the requirement of polymerases or ligases, respectively, in order to achieve amplification. In addition to being expensive, such enzymes exhibit lot-to-lot variations in activity and in the concentration of undesired nuclease contaminants. Such variations detract further from the reliability of these methods.

In order to overcome the use of enzymes in the amplification process, Segev disclosed (international PCT application US 94/06690) a new chemical process, aimed at the non-enzymatic amplification of any specific nucleic acid sequence. In this method, named Chemical Amplification Reaction (CAR), two oligonucleotide probe complement pairs are used, wherein:

(a) the first oligonucleotide probe complement pair consists of oligonucleotide probe 1 and oligonucleotide probe 1', and the second oligonucleotide probe complement pair consists of oligonucleotide probe 2 and oligonucleotide probe 2';

(b) Oligonucleotide probe 1 includes a long sequence H and a short sequence I; oligonucleotide probe 1' includes a long sequence H' and a short sequence I'; Oligonucleotide probe 2 includes a long sequence J and a short sequence K; oligonucleotide probe 2' includes a long sequence J' and a short sequence K';

(c) Oligonucleotide probes 1 and 2 form a first oligonucleotide pair, whereas oligonucleotide probes 1' and 2' form a second oligonucleotide pair; long sequence H of oligonucleotide probe 1 and long sequence J of oligonucleotide probe 2 are complementary to adjacent portions of the target sequence; and long sequence H' of oligonucleotide probe 1' and long sequence J' of oligonucleotide probe 2' are complementary to adjacent portions of the target complementary sequence;

(d) Short sequence I of oligonucleotide probe 1 is complementary to short sequence K of oligonucleotide probe 2 and short sequence I' of oligonucleotide probe 1' is complementary to short sequence K' of oligonucleotide probe 2'; Short sequences do not hybridize to the target sequence.

(e) The sugar or base moieties of nucleotides consisting short sequences are modified with chemical functionality groups X and Y, wherein X and Y groups could form a chemical bond. The oligonucleotide probes used for CAR are

shown in Figure 1 wherein the vertical line demarcate the border between long and short sequences.

- (f) When these oligonucleotide probes are made in contact with a double-stranded sequence, composed of a target sequence and a target complementary sequence, the hybridizations shown in Figure 2 occur.

In the CAR method, Long sequences serve for target oriented hybridization while short sequences serve a dual function: (a) they shield and therefore restrict chemical active groups X and Y from interacting with one another when long sequences are not hybridized with the target sequence; (b) they bring chemical active groups X and Y to a proximity and orientation facilitating their interaction when long sequences are hybridized with the target sequence, leading to hybridization between the short sequences.

However, this method has a major drawback since a cross-like structure (shown in Figure 3) of a high thermodynamic stability may form, and upon amplification may result in a template independent false-positive amplification products.

Another drawback of the above method is its inability to discriminate among target nucleic acid sequences which differ by a minute sequence alteration, such as a point mutation, i.e. a single base pair alteration. Therefore, the CAR method is not suitable for the detection of minute sequence alterations such as point mutations.

It is an object of the present invention to provide a simple, rapid and highly accurate method of amplification and detection of target sequences that uses neither polymerase nor ligase, and that reduced spurious background signals and, therefore, improves the reliability of a chemical amplification reaction of a nucleic acid.

It is another object of the present invention to provide a sensitive method for chemical amplification of nucleic acids which is sensitive enough to discriminatively amplify nucleic acid sequences which differ by a minute sequence alteration, such as for example a single base alteration, i.e., a point mutation.

It is yet another object of the present invention to provide a diagnostic kit to be used for carrying out the above method of the invention, which will enable *in situ* detection, that is a detection procedure that yields a detectable signal associated with amplification, without the need to reopen the reaction vessel post  
5 amplification, which procedure reduces the problem of contamination by previous amplification products and, therefore, reduces false-positive results.

SUMMARY OF THE INVENTION:

The present invention concerns a method and kit for detecting a target nucleic acid sequence which may be present in a test sample. The method is  
5 sensitive enough to discriminate among sequences which differ by a minute sequence alteration such as, for example, a point mutation, i.e. a single base pair alteration. The method may employ both an amplification procedure and a detection procedure. These and other objectives, as will become apparent to those who are skilled in the art, have been met by providing a process for  
10 amplifying and detecting, in a sample, a single-stranded nucleic acid target molecule consisted of a target sequence, or a double-stranded nucleic acid target molecule consisted of a target sequence and a target complementary sequence.

Amplification is accomplished through the use of a minimum of two  
15 oligonucleotide probe complement pairs, wherein members oligonucleotide probes from both pair of oligonucleotide probe complement pairs form two oligonucleotide probe pairs which are complementary to a given portion of the target nucleic acid sequence and the target nucleic acid complementary sequence, should it exist, which act as templates. The nucleotide sequence of  
20 the members of each pair of oligonucleotide probes is selected to be complementary to a different portion of the target nucleic acid sequence, so as each oligonucleotide probe pair essentially cover a predefined nucleotide stretch of the target sequence in a non-contiguous manner. The mode of amplification imposed by these unique oligonucleotide probe pairs consists of the following  
25 steps:

contacting a first oligonucleotide probe complement pair and a second oligonucleotide probe complement pair with stretches of nucleotide bases present in the nucleic acids of interest, wherein:

30

(i) the first oligonucleotide probe complement pair consists of oligonucleotide probe 1 and oligonucleotide probe 1' and the second oligonucleotide probe complement pair consists of oligonucleotide probe 2 and oligonucleotide probe 2';

35

(ii) oligonucleotide probe 1 consists of a targeting sequence A, which includes a long part  $\alpha$  and a short part  $\alpha'$ , and of a protecting sequence B; oligonucleotide probe 1' consists of a targeting sequence A' and a protecting sequence B';

- 5 (iii) oligonucleotide probe 2 consists of a targeting sequence C;  
oligonucleotide probe 2' consists of a targeting sequence C'  
which includes a long part  $\gamma$  and a short part  $\gamma'$ ;
- (iv) part  $\alpha$  of targeting sequence A of oligonucleotide probe 1 and  
targeting sequence A' of oligonucleotide probe 1' are  
complementary to each other;
- 10 (v) targeting sequence C of oligonucleotide probe 2 and part  $\gamma$  of  
targeting sequence C' of oligonucleotide probe 2' are  
complementary to each other; part  $\gamma'$  of targeting sequence C' of  
oligonucleotide probe 2' and part  $\alpha'$  of targeting sequence A of  
oligonucleotide probe 1 are complementary to each other;
- 15 (vi) oligonucleotide probes 1 and 2 form a first oligonucleotide pair  
wherein targeting sequence A of oligonucleotide probe 1 and  
targeting sequence C of oligonucleotide probe 2 are  
complementary to adjacent portions of the target sequence;
- 20 (vii) oligonucleotide probes 1' and 2' form a second oligonucleotide  
pair wherein targeting sequence A' of oligonucleotide probe 1' and  
targeting sequence C' of oligonucleotide probe 2' are  
complementary to adjacent portions of the target complementary  
sequence;
- 25 (viii) protecting sequence B do not hybridize to the target sequence  
when targeting sequence A and targeting sequence C hybridize to  
the target sequence;
- 30 (ix) protecting sequence B' do not hybridize to the target  
complementary sequence when targeting sequence A' and targeting  
sequence C' hybridize to the target complementary sequence;
- 35 (x) in the junction of targeting sequence A and protecting sequence B,  
a chemical functionality group X1 is attached to the sugar or base  
moiety of the last nucleotide in targeting sequence A of  
oligonucleotide probe 1; the sugar or base moiety of the end-  
nucleotide of targeting sequence C of oligonucleotide probe 2 is



modified with chemical functionality group Y1; chemical functionality group X1 is reactive with chemical functionality group Y1;

5 (xi) in the junction of targeting sequence A' and protecting sequence B', a chemical functionality group X2 is attached to the sugar or base moiety of the last nucleotide in targeting sequence A' of oligonucleotide probe 1'; the sugar or base moiety of the end-nucleotide of targeting sequence C' of oligonucleotide probe 2' is  
10 modified with chemical functionality group Y2; chemical functionality group X2 is reactive with chemical functionality group Y2;

(xii) when targeting sequence A and targeting sequence C hybridize to  
15 target sequence, chemical functionality group X1 reacts with chemical functionality group Y1 to form a chemical bond, and a complementary strand of joined oligonucleotide (i.e. amplification) product is formed; when targeting sequence A' and targeting  
20 sequence C' hybridize to target complementary sequence, chemical functionality group X2 reacts with chemical functionality group Y2 to form a chemical bond, and a complementary strand of amplification product is formed;

25 providing hybridization conditions to enable targeting sequence A of oligonucleotide probe 1 and targeting sequence C of oligonucleotide probe 2 to hybridize with adjacent portions of the target sequence and to enable targeting sequence A' of oligonucleotide probe 1' and targeting sequence C' of oligonucleotide probe 2' to hybridize with adjacent  
30 portions of the target complementary sequence;

providing conditions which will enable the joining oligonucleotide probe 1 and oligonucleotide probe 2, hybridized after step (b) to adjacent  
35 portions of the target sequence, to each other by forming a chemical bond between chemical functionality groups X1 and Y1, thereby forming a first joined oligonucleotide product having the target complementary sequence;

providing conditions which will enable the joining of oligonucleotide probe 1' and oligonucleotide probe 2', hybridized after step (b) to adjacent portions of the target complementary sequence, to each other, by

forming a chemical bond between chemical functionality groups X2 and Y2, thereby forming a second joined oligonucleotide product having the target sequence;

- 5 (e) treating the sample under denaturing conditions;
- (f) repeating steps (b) through (e) a desired number of times; and
- (g) detecting the joined oligonucleotide products.

10

The method of the present invention is also suitable for the detection of a minute sequence alteration, such as for example a point mutation, i.e. a single base pair alteration, in a target nucleic acid sequence. To this end, two sets each of four oligonucleotide probes are designed. The first set is aimed at the amplification of a wild-type target nucleic acid sequence and of a wild-type target nucleic acid complementary sequence, whereas the second set is aimed at the amplification of a mutant target nucleic acid sequence and of a mutant target nucleic acid complementary sequence. The oligonucleotide probe sets are employed according to the following steps:

20

- (a) contacting a first and a second oligonucleotide probes set with stretches of nucleotide bases present in the nucleic acids of interest, wherein:
- (i) the first oligonucleotide probes set is designed to amplify the wild-type sequences and includes four oligonucleotide probes designated 1, 1', 2 and 2' which are similar in their built-up to the ones described above; oligonucleotide probes 1 and 1' form a first oligonucleotide probe complementary pair; oligonucleotide probes 2 and 2' form a second oligonucleotide probe complementary pair; oligonucleotide probes 1 and 2 form a first oligonucleotide probe pair; oligonucleotide probes 1' and 2' form a second oligonucleotide probe pair;
- (ii) the second oligonucleotide probes set is designed to amplify the mutant sequences and includes four oligonucleotide probes designated 3, 3', 4 and 4' which are similar in built-up to oligonucleotide probes 1, 1', 2 and 2' of the first oligonucleotide probes set, respectively; oligonucleotide probes 3 and 3' form a third oligonucleotide probe complementary pair; oligonucleotide

25

30

35

probes 4 and 4' form a fourth oligonucleotide probe complementary pair; oligonucleotide probes 3 and 4 form a third oligonucleotide probe pair; oligonucleotide probes 3' and 4' form a fourth oligonucleotide probe pair;

5

(iii) oligonucleotide probes 1 and 3 are each consisted of a targeting sequence A, which includes a long part  $\alpha$  and a short part  $\alpha'$ , and of a protecting sequence B and D, respectively; oligonucleotide probe 1' and 3' are each consisted of a targeting sequence A' and a protecting sequence B' and D', respectively;

10

(iv) oligonucleotide probe 2 and 4 are each consisted of a targeting sequence C; oligonucleotide probe 2' and 4' are each consisted of a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ ;

15

(v) part  $\alpha$  of targeting sequences A of oligonucleotide probes 1 and 3 and targeting sequences A' of oligonucleotide probes 1' and 3' are complementary to each other, respectively;

20

(vi) targeting sequences C of oligonucleotide probes 2 and 4 and part  $\gamma$  of targeting sequences C' of oligonucleotide probes 2' and 4' are complementary to each other, respectively; part  $\gamma'$  of targeting sequences C' of oligonucleotide probes 2' and 4' and part  $\alpha'$  of sequences A of oligonucleotide probes 1 and 3 are complementary to each other, respectively;

25

(vii) the sequence of oligonucleotide probes 3' and 4 of the second oligonucleotide probes set is identical or closely similar to the sequence of oligonucleotide probes 1' and 2 of the first oligonucleotide probes set, respectively; the sequence of oligonucleotide probes 3 and 4' of the second oligonucleotide probes set differ from that of oligonucleotide probes 1 and 2' of the first oligonucleotide probes set, respectively, in a position of a sequence alteration to be determined, so that oligonucleotide probes 1 and 2' are fully complementary to the wild-type target sequence and the wild-type target complementary sequence, respectively, at that position, and oligonucleotide probes 3 and 4' are fully complementary to the mutant target sequence and the

30

35

mutant target complementary sequence, respectively, at that position;

- 5 (viii) targeting sequence A of oligonucleotide probe 1 and targeting sequence C of oligonucleotide probe 2 are complementary to adjacent portions of the wild-type target sequence; targeting sequence A of oligonucleotide probe 3 and targeting sequence C of oligonucleotide probe 4 are complementary to adjacent portions of the mutant target sequence;
- 10 (ix) targeting sequence A' of oligonucleotide probe 1' and targeting sequence C' of oligonucleotide probe 2' are complementary to adjacent portions of the wild-type target complementary sequence; targeting sequence A' of oligonucleotide probe 3' and targeting sequence C' of oligonucleotide probe 4' are complementary to adjacent portions of the mutant target complementary sequence;
- 15 (x) protecting sequences B and D do not hybridize to the wild-type or mutant target sequences, respectively, when targeting sequences A and targeting sequences C hybridize to these target sequences;
- 20 (xi) protecting sequences B' and D' do not hybridize to the wild-type or mutant target complementary sequences, respectively, when targeting sequences A' and targeting sequences C' hybridize to these target complementary sequence;
- 25 (xii) in the junction of targeting sequence A and protecting sequence B of oligonucleotide probe 1, a chemical functionality group X1 is attached to the sugar or base moiety of the last nucleotide of sequence A; the sugar or base moiety of the end-nucleotide of targeting sequence C of oligonucleotide probe 2 is modified with chemical functionality group Y1; chemical functionality group X1 is reactive with chemical functionality group Y1;
- 30 (xiii) in the junction of targeting sequence A and protecting sequence D of oligonucleotide probe 3, a chemical functionality group X3 is attached to the sugar or base moiety of the last nucleotide of sequence A; the sugar or base moiety of the end-nucleotide of
- 35

targeting sequence C of oligonucleotide probe 4 is modified with chemical functionality group Y3; chemical functionality group X3 is reactive with chemical functionality group Y3;

- 5           (xiv) in the junction of targeting sequence A' and protecting sequence B' of oligonucleotide probe 1', a chemical functionality group X2 is attached to the sugar or base moiety of the last nucleotide of sequence A'; the sugar or base moiety of the end-nucleotide of targeting sequence C' of oligonucleotide probe 2' is modified with chemical functionality group Y2; chemical functionality group X2 is reactive with chemical functionality group Y2;
- 10
- (xv) in the junction of targeting sequence A' and protecting sequence D' of oligonucleotide probe 3', a chemical functionality group X4 is attached to the sugar or base moiety of the last nucleotide of sequence A'; the sugar or base moiety of the end-nucleotide of targeting sequence C' of oligonucleotide probe 4' is modified with chemical functionality group Y4; chemical functionality group X4 is reactive with chemical functionality group Y4;
- 15
- (xvi) when targeting sequence A and targeting sequence C of oligonucleotide probes 1 and 2, respectively, hybridize to a wild-type target sequence, chemical functionality group X1 reacts with chemical functionality group Y1 to form a chemical bond, and a complementary strand of wild-type joined oligonucleotide product is formed; when targeting sequence A' and targeting sequence C' of oligonucleotide probes 1' and 2' hybridize to a wild-type target complementary sequence, chemical functionality group X2 reacts with chemical functionality group Y2 to form a chemical bond, and a strand of wild-type joined oligonucleotide product is formed;
- 20
- (xvii) when targeting sequence A and targeting sequence C of oligonucleotide probes 3 and 4, respectively, hybridize to a mutant target sequence, chemical functionality group X3 reacts with chemical functionality group Y3 to form a chemical bond, and a complementary strand of mutant joined oligonucleotide product is formed; when targeting sequence A' and targeting sequence C' of oligonucleotide probes 3' and 4', respectively, hybridize to a mutant target complementary sequence, chemical functionality group X4
- 25
- 30
- 35

reacts with chemical functionality group Y4 to form a chemical bond, and a strand of mutant joined oligonucleotide product is formed;

- 5 (b) providing hybridization conditions to enable:
- (i) targeting sequence A of oligonucleotide probe 1 and  
targeting sequence C of oligonucleotide probe 2 to hybridize with  
adjacent portions of the wild-type target sequence;
- 10 (ii) targeting sequence A' of oligonucleotide probe 1' and  
targeting sequence C' of oligonucleotide probe 2' to hybridize with  
adjacent portions of the wild-type target complementary sequence;
- 15 (iii) targeting sequence A of oligonucleotide probe 3 and  
targeting sequence C of oligonucleotide probe 4 to hybridize with  
adjacent portions of the mutant target sequence;
- 20 (iv) targeting sequence A' of oligonucleotide probe 3' and  
targeting sequence C' of oligonucleotide probe 4' to hybridize with  
adjacent portions of the mutant target complementary sequence;
- (c) providing conditions which will enable the joining of oligonucleotide  
probe 1 and oligonucleotide probe 2, hybridized after step (b) to adjacent  
25 portions of the wild-type target sequence, to each other, by forming a  
chemical bond between chemical functionality groups X1 and Y1, thereby  
forming a first joined oligonucleotide product having the wild-type target  
complementary sequence;
- 30 (d) providing conditions which will enable the joining of oligonucleotide  
probe 1' and oligonucleotide probe 2', hybridized after step (b) to  
adjacent portions of the wild-type target complementary sequence, to each  
other, by forming a chemical bond between chemical functionality groups  
X2 and Y2, thereby forming a second joined oligonucleotide product  
35 having the wild-type target sequence;
- (e) providing conditions which will enable the joining of oligonucleotide  
probe 3 and oligonucleotide probe 4, hybridized after step (b) to adjacent  
portions of the mutant target sequence, to each other, by forming a

chemical bond between chemical functionality groups X3 and Y3, thereby forming a first joined oligonucleotide product having the mutant target complementary sequence;

- 5 (f) providing conditions which will enable the joining of oligonucleotide probe 3' and oligonucleotide probe 4', hybridized after step (b) to adjacent portions of the mutant target complementary sequence, to each other, by forming a chemical bond between chemical functionality groups X4 and Y4, thereby forming a second joined oligonucleotide product  
10 having the mutant target sequence;
- (g) treating the sample under denaturing conditions;
- (h) repeating steps (b) through (g) a desired number of times; and  
15
- (i) detecting the joined oligonucleotide products.

Also according to the present invention, there is provided a diagnostic kit for amplifying specific nucleotide sequences a sample, consisting of two or more  
20 oligonucleotide probes complementary pairs and at least one buffer.

A straight forward approach to achieve an *in situ* detection of amplification products, that is a detection procedure which does not involve opening the test tubes post amplification, is to design the chemical functionality  
25 groups of the X types and of the Y types such as they form a detectable compound when a chemical bond is formed between them.

The detectable compound may for example be detected colourimetrically in O.D. units or flourimetrically depending on the chemical nature of the  
30 compound. The compound may also be detected via directly or indirectly labeled antibodies, for example a monoclonal antibody, raised against the compound.

During the execution of the amplification procedure described above, at  
35 least two single-stranded products B and B' and/or D and D' are formed. These single-stranded sequences are unique to joined oligonucleotide products, therefore, some or all, are employed to detected the presence of joined oligonucleotide products in accordance with two alternative detection procedures. As a matter of simplicity the detection procedure will be described

herein for the first oligonucleotide probes set. A similar approach may of course be ascribed to the second oligonucleotide probes set.

5 In the first detection procedure employed are two labeled detection oligonucleotide probes in a detection process which involves proximity energy transfer labeling. As a first detection oligonucleotide probe serve protecting sequence B and/or B' of oligonucleotide probes 1 and 1', respectively. To the first detection oligonucleotide probe conjugated is a proximity label moiety R1. Conjugated to the second detection oligonucleotide probe B.1 and/or B'.1 is a  
10 corresponding second proximity label moiety R2. The second detection oligonucleotide probes B.1 and B'.1 may also be connected directly or indirectly to form a continuous molecule B.1-B'.1. The second detection oligonucleotide probes B.1 and B'.1 are complementary to protecting sequence B and B', respectively. The first and second labeled detection oligonucleotide probes  
15 hybridize to one another and therefore bring the proximity label moieties R1 and R2 to a proximity which is sufficient for their interaction to produce a detectable signal. When the two labeled detection oligonucleotide probes are hybridized, proximity labeling moieties R1 and R2 are brought into proximity that enables an energy transfer reaction between them to occur, resulting in a measurable energy  
20 emission.

The second detection procedure of the amplification products is based upon the release of a label moiety L conjugated to single-stranded B and/or B' sequences which are incorporated into joined oligonucleotide products, and the  
25 removal of all double-stranded B and B' sequences along with label moieties L conjugated to them from the test vessel via an affinity separation moiety S conjugated to oligonucleotide probes 1 and/or 1'. The single-stranded B and B' sequences may be nucleated post amplification via the use of a single-stranded specific nuclease, or by a suitable chemical procedure, resulting in the release of  
30 the label moiety L conjugated to them to the surrounding solution. To one or more locations of one or more of the oligonucleotide probes used in the amplification reaction, conjugated is one or more affinity separation moiety S. The affinity separation moiety S is characterized by its ability to bind a counterpart moiety S' in high affinity. The counterpart affinity separation  
35 moiety S' is preferably attached to a solid support. Following amplification, a single-strand specific nucleolytic process is used to degrade single-stranded sequences B and B' which are incorporated to joined oligonucleotide products. The result of the nucleolysis is the release of the label moiety L to the solution, in an amount which is proportional to the level of amplification. Label moieties



L that where not thus released, these are label moieties which are conjugated to sequences B or B' that were not incorporated into joined oligonucleotide products, are removed by affinity separation. The released label moieties L may thus be detected.

5

Also according to the present invention, there is provided a diagnostic kit for detecting the presence of specific nucleotide sequences in samples, consisting: (a) two or more oligonucleotide probes complementary pairs; (b) two or more detection oligonucleotide probes conjugated to a proximity labeling moiety; and (c) at least one buffer;

10

or alternatively consisting: (a) two or more oligonucleotide probes complementary pairs, one or more are conjugated to a separation moiety, and one or more are conjugated to a label moiety; (b) a single-strand specific nuclease; and (e) a solid support for affinity separation of joined oligonucleotide products.

15

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings, wherein:

5

FIG. 1 is a schematic depiction of the oligonucleotide probes used in the chemical amplification reaction (CAR) method of the prior art.

10 FIG. 2 is a schematic depiction of the hybridizations characterizing oligonucleotide probes of the CAR method when contacted with a target nucleic acid sequence and a target nucleic acid complementary sequence.

15 FIG. 3 is a schematic depiction a cross-like structure of a high thermodynamic stability characterizing the oligonucleotide probes used under the CAR method, which upon amplification may result in a template independent false-positive amplification products.

20 FIG. 4 is a schematic depiction of oligonucleotide probe pairs used for amplification of nucleic acid sequences according to the method of the present invention.

25 FIG. 5 is a schematic depiction of twelve alternative oligonucleotide probe pairs used for amplification of nucleic acid sequences according to the method of the present invention.

FIG. 6 is a schematic depiction of the built-up of the oligonucleotide probes used for amplification of nucleic acid sequences according to the method of the present invention.

30 FIG. 7 is a schematic depiction of the hybridizations characterizing oligonucleotide probes of the method of the present invention, when contacted with a target nucleic acid sequence and a target nucleic acid complementary sequence.

35 FIG. 8 is a schematic depiction of a structure of a high thermodynamic stability the oligonucleotide probes used under the method of the present invention.

FIG. 9 is a schematic depiction of the formation of joined oligonucleotide products during the amplification of a nucleic acid sequence according to the method of the present invention.

5        FIG. 10 shows adenine derivatives A1, A2, A3 and A4 modified with a chemical functionality group Z.

FIG. 11 shows cytidine derivatives C1, C2, C3 and C4 modified with a chemical functionality group Z.

10

FIG. 12 shows guanine derivatives G1, G2, G3 and G4 modified with a chemical functionality group Z.

15        FIG. 13 shows thymidine derivatives T1, T2, T3 and T4 modified with a chemical functionality group Z.

FIG. 14 shows uridine derivatives U1, U2, U3 and U4 modified with a chemical functionality group Z.

20        FIG. 15 shows the preferred embodiment for a Diels-Alder reaction is the system where uridine is modified at the C-5 position to form a Diene which functions as a chemical functionality group, X, for example in oligonucleotide probes 1, 1', 3 and 3'. Whereas in the end of targeting sequences C and C', the sugar is modified at the C-2' position by 2-butenedioic acid which functions as a  
25        chemical functionality group, Y, for example.

FIG. 16 shows a generalized illustrations of hybridized targeting sequence A and targeting sequence C, or of targeting sequence A' and targeting sequence C' to the target nucleic acid sequence or the target nucleic acid complementary  
30        sequence, with chemical functionality groups attached to the nucleotide bases.

FIG. 17 shows a generalized illustration of oligonucleotide probes hybridized to a double-stranded target molecule and joined by chemical functionality groups to form a first and a second joined oligonucleotide products.

35

FIG. 18 is a schematic depiction of the first cycle in the amplification procedure of a double-stranded sequence which includes hybridization of the oligonucleotide probes to the target sequence and the target complementary

sequence and joining of the oligonucleotide probes via the chemical functionality groups to form joined oligonucleotide products.

FIG. 19 is a schematic depiction of the formation of joined  
5 oligonucleotide probes via the chemical functionality groups which is followed by denaturation of the first and second joined oligonucleotide products from the target sequence and the target complementary sequences, respectively.

FIG. 20 shows a generalized illustration of the ability of the first and  
10 second joined oligonucleotide products to act as a template for the formation of additional second and first joined oligonucleotide products, respectively, during the second and all subsequent cycles of the amplification process.

FIG. 21 shows a the similarities and differences among the  
15 oligonucleotide probes constituting the first and second oligonucleotide probe sets aimed at the discriminative amplification of nucleic acid sequences which differ by a n A  $\rightarrow$  G point mutation.

FIG. 22 shows a case in which ultimate chemical functionality groups  
20 which are ones that distort the tertiary structure of the hybridized sequences to a permissible degree that enables the use of oligonucleotide probe complementary pairs that are of the same length are used in which the modified nucleotides themselves, to which the chemical functionality groups are conjugated, act as the amplification discriminative sequences.

25  
FIG. 23 is a schematic depiction of the single-stranded B and B' protecting sequences formed during the amplification procedure of the method of invention.

30  
FIG. 24 is a schematic depiction of the labeled detection oligonucleotide probes employed in an *in situ* detection process which involves proximity energy transfer labeling.

35  
FIG. 25 is a schematic depiction of the labeled detection oligonucleotide probes employed in an *in situ* detection process which involves proximity energy transfer labeling in which hybridization leads to the formation of aggregates composed of a variable number of joined oligonucleotide products linked to one another via the B.1-B'.1 molecule.

FIG. 26 is a schematic depiction of an *in situ* detection method which involves the release and the detection of a label moiety L from single-stranded B and B' protecting sequences via the activity of a single-stranded specific nuclease and the removal of label moieties L not thus released via affinity separation.

5

FIG. 27 is a schematic depiction of a reaction tube which serve for affinity separation.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The present invention is of a novel non-enzymatic method for amplifying and detecting existing target nucleic acid sequences in a test sample and of kits for use in implementing the method. The method of the present invention may employ both an amplification procedure and a detection procedure and is also useful in the detection of minute sequence alterations such as point mutations, i.e. a single base pair alteration.

10 The principles and operation of a method according to the present invention may be better understood with reference to the drawings and the accompanying description.

15 The present invention will be described in detail with emphasis on a method for identifying the presence of a target nucleic acid sequence in an examined sample and on a method for identifying minute sequence alterations in genes, which alterations are associated with genetic disorders. While the later applications of the method of the invention are presently preferred, this is by no means the only applications of the invention as will no doubt be appreciated by those skilled in the art. For example, the method has various other applications including, but not limited to, the detection of specific genetic sequences in a sample such as those associated with certain genetic polymorphisms, such as, for example, in the HLA locus; in testing of paternity and in forensic medicine; and in the diagnosis of certain cancers.

25

As used herein, the following terms have their definitions designated below.

Target nucleic acid sequence

30

The process of the present invention can produce a geometric amplification of a target nucleic acid sequence, provided that at least part of the nucleotide sequence is known in sufficient detail that complementary oligonucleotide probe pairs can be synthesized. The "amplification" that is achieved through the methods of the present invention denotes an increase in the amount of desired nucleic acid molecules present in a reaction vessel. "Substantial amplification" refers to greater than about 100-fold amplification. The target nucleic acid sequence that is amplified by the method of the present invention may be single-stranded or double-stranded DNA, single-stranded or

double-stranded RNA, single-stranded or double-stranded protein nucleic acid (PNA) or a hybrid of DNA, RNA and/or PNA. Since no enzymes are used in the amplification process of the present invention, therefore, the target sequence may be in a purified or a non-purified form. The sample of nucleic acids can be drawn from any source and may be natural or synthetic. The sample of nucleic acids may be made up of deoxyribonucleic acids, ribonucleic acids, or copolymers of deoxyribonucleic acid and ribonucleic acid or combinations thereof. The nucleic acid of interest can be synthesized enzymatically *in vitro*, or be synthesized non-enzymatically. The sample containing the nucleic acid or acids of interest can also comprise extragenomic DNA from an organism, RNA transcripts thereof, or cDNA prepared from RNA transcripts thereof. Also, the nucleic acid or acids of interest can be synthesized by the polymerase or ligase chain reaction.

The cells that contain the target nucleic acid sequence, could be lysed in the presence of the reagents used in implementing the method. Typically, the sample is treated to a sufficient degree such that extraneous materials which might otherwise interfere with amplification of the nucleic acid are removed. For example, the preparation of a serum sample for analysis using the method of the invention may consist incubation of the serum sample for 1 hr. at 70°C in the presence of proteinase K at a concentration of 2.5 mg/ml in 25 ml MOPS (pH 6.5), 2.5 mM EDTA and 0.5% SDS. Following this treatment, the sample is ready for amplification without any further purification steps.

The nucleic acid sample contains the specific nucleotide sequences to which the oligonucleotide probes hybridize. If a target sequence is double-stranded, it contains a target sequence and its complement called the target complementary sequence. The target sequence can be as short as twelve nucleotides, but preferably contains at least sixteen nucleotides and more preferably at least twenty nucleotides. There is no maximum number of nucleotides in the target sequence or target complementary sequence, which can constitute either a portion of the nucleic acid sample or the entire nucleic acid sample.

Among the molecules which may be amplified using the invented method included are genetic material in the form of DNA or RNA obtained from any naturally occurring prokaryotes such as for example, pathogenic or non-pathogenic bacteria including but not limited to species of *Escherichia*, *Salmonella*, *Clostridium*, *Chlamydia*, etc.; eukariots such as for example,

protozoans and parasites, fungi, yeast, higher plants, lower and higher animals, including mammals and humans and cells in tissue culture; or viruses such as for example, Herpes viruses, HIV, influenza virus, Epstein-Barr virus, hepatitis B virus, etc. The nucleic acid molecules can also be any nucleic acid molecule  
5 which has been or can be chemically or enzymatically synthesized.

DNA or RNA from these sources may, for example, be found in samples of a bodily fluid from an animal, including a human, such as, but not limited to, blood, urine, lymphatic fluid, synovial fluid, bile, phlegm, saliva, menstrual fluid  
10 and semen. In addition, samples containing DNA or RNA may, for example, be found in fluids from a plant, such as, but not limited to, xylem fluid, phloem fluid and plant exudates. Samples containing DNA or RNA may, for example also be found in non-living sources such as, but not limited to, food, sewage, forensic samples, lakes, reservoirs, rivers and oceans.

15 Although the nucleic acid target molecule which is to be amplified by the method of the present invention may be in either a double-stranded or a single-stranded form, in the case where the nucleic acid target molecule is double-stranded it is preferably first treated by a denaturation agent to render the two  
20 strands into a single-stranded, or partially single-stranded form, at the start of the amplification reaction, by methods known in the art such as heating, alkali treatment, or by enzymatic methods. General methods for accomplishing this treatment are provided by Sambrook, J. *et al.* In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,  
25 NY (1989).

### Complementarity

As used herein, two sequences are said to "hybridize" to one another if  
30 they are capable of forming an anti-parallel double-stranded nucleic acid structure. Two nucleic acid molecules are said to be "complementary" if they can hybridize to one another with sufficient stability to permit them to remain annealed to one another under at least conventional "low stringency" conditions. (These conditions are described in Sambrook, as above).

35

Thus, two complementary molecules need not exhibit precise complementarity, but need only be sufficiently complementary in sequence to be able to form a stable double-stranded structure. Departures from complete complementarity are therefore permissible, as long as such departures are not



sufficient to completely preclude hybridization to form a double-stranded structure.

#### Oligonucleotide probe complement pair

5

The term "oligonucleotide probe complement pair" as used herein refers to two different oligonucleotide probes designated, for example, oligonucleotide probe 1 and oligonucleotide probe 1' or oligonucleotide probe 2 and oligonucleotide probe 2', as shown in Figure 4. As will shortly be demonstrated in details, oligonucleotide probes 1 and 1', oligonucleotide probes 2 and 2', oligonucleotide probes 3 and 3' as well as oligonucleotide probes 4 and 4', share sequence regions which are complementary. Each oligonucleotide probe of a complement pair of oligonucleotide probes can be equal or preferably, as shown in the Figure, unequal in length to its co-member. It should be understood that more than two oligonucleotide probe complement pairs per target sequence or target complementary sequence could be used during the execution of the method of the present invention.

10

15

#### Oligonucleotide probe Pair

20

The term "oligonucleotide probe pair", as used herein, refers to the grouping of oligonucleotide probes 1 and 2 as a first "oligonucleotide probe pair", the grouping of oligonucleotide probes 1' and 2' as a second "oligonucleotide probe pair", the grouping of oligonucleotide probes 3 and 4 as a third "oligonucleotide probe pair" and the grouping of oligonucleotide probes 3' and 4' as a fourth "oligonucleotide probe pair".

25

The oligonucleotide probes are preferably constructed from deoxyribonucleotides, though ribonucleotides and nucleotide analogs such as but not limited to protein nucleic acid (PNA), are acceptable substitutes.

30

Referring to the first oligonucleotide probe complement pair in Figure 4, oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; Oligonucleotide probe 1' has a targeting sequence A' and a protecting sequence B'; oligonucleotide probe 2 has a targeting sequence C; and oligonucleotide probe 2' has a targeting sequence C'. X and Y are chemical functionality groups, wherein X and Y groups could form a chemical bond. The oval shape, as will shortly be described, is a single-stranded loopout, is a part of targeting sequence A

35

and is complementary to the single-stranded sequence portion of targeting sequence C'.

As is understood by ones with skills in the art, twelve slightly different versions exist for the sequences arrangement among these oligonucleotide probes. These versions are shown in Figure 5 and include: (1) oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; oligonucleotide probe 1' has a targeting sequence A' which is shorter than targeting sequence A of oligonucleotide probe 1; oligonucleotide probe 2 has a targeting sequence C; oligonucleotide probe 2' has a targeting sequence C' which is longer than targeting sequence C of oligonucleotide probe 2 and a protecting sequence B'; (2) oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; oligonucleotide probe 1' has a targeting sequence A' which is longer than targeting sequence A of oligonucleotide probe 1; oligonucleotide probe 2 has a targeting sequence C; oligonucleotide probe 2' has a targeting sequence C' which is shorter than targeting sequence C of oligonucleotide probe 2 and a protecting sequence B'; (3) oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; oligonucleotide probe 1' has a targeting sequence A' which equals in length to targeting sequence A of oligonucleotide probe 1; oligonucleotide probe 2 has a targeting sequence C; oligonucleotide probe 2' has a targeting sequence C' which equals in length to targeting sequence C of oligonucleotide probe 2 and a protecting sequence B'; (4) oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; oligonucleotide probe 1' has a targeting sequence A' which is shorter than targeting sequence A of oligonucleotide probe 1 and a protecting sequence B'; oligonucleotide probe 2 has a targeting sequence C; oligonucleotide probe 2' has a targeting sequence C' which is longer than targeting sequence C of oligonucleotide probe 2; (5) oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; oligonucleotide probe 1' has a targeting sequence A' which is longer than targeting sequence A of oligonucleotide probe 1 and a protecting sequence B'; oligonucleotide probe 2 has a targeting sequence C; oligonucleotide probe 2' has a targeting sequence C' which is shorter than targeting sequence C of oligonucleotide probe 2; (6) oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; oligonucleotide probe 1' has a targeting sequence A' which equals in length to targeting sequence A of oligonucleotide probe 1 and a protecting sequence B'; oligonucleotide probe 2 has a targeting sequence C; oligonucleotide probe 2' has a targeting sequence C' which equals in length to targeting sequence C of oligonucleotide probe 2; (7) oligonucleotide probe 1 has a targeting sequence A; oligonucleotide probe 1' has a targeting sequence A'

which is shorter than sequence A of oligonucleotide probe 1; oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B; oligonucleotide probe 2' has a targeting sequence C' which is longer than targeting sequence C of oligonucleotide probe 2 and a protecting sequence B'; (8) oligonucleotide probe 1 has a targeting sequence A; oligonucleotide probe 1' has a targeting sequence A' which is longer than sequence A of oligonucleotide probe 1; oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B; oligonucleotide probe 2' has a targeting sequence C' which is shorter than targeting sequence C of oligonucleotide probe 2 and a protecting sequence B'; (9) oligonucleotide probe 1 has a targeting sequence A; oligonucleotide probe 1' has a targeting sequence A' which equals in length to sequence A of oligonucleotide probe 1; oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B; oligonucleotide probe 2' has a targeting sequence C' which equals in length to targeting sequence C of oligonucleotide probe 2 and a protecting sequence B'; (10) oligonucleotide probe 1 has a targeting sequence A; oligonucleotide probe 1' has a targeting sequence A' which is shorter than targeting sequence A of oligonucleotide probe 1 and a protecting sequence B; oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B'; oligonucleotide probe 2' has a targeting sequence C' which is longer than targeting sequence C of oligonucleotide probe 2; (11) oligonucleotide probe 1 has a targeting sequence A; oligonucleotide probe 1' has a targeting sequence A' which is longer than targeting sequence A of oligonucleotide probe 1 and a protecting sequence B; oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B'; oligonucleotide probe 2' has a targeting sequence C' which is shorter than targeting sequence C of oligonucleotide probe 2; (12) oligonucleotide probe 1 has a targeting sequence A; oligonucleotide probe 1' has a targeting sequence A' which equals in length to targeting sequence A of oligonucleotide probe 1 and a protecting sequence B; oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B'; oligonucleotide probe 2' has a targeting sequence C' which equals in length to targeting sequence C of oligonucleotide probe 2. It is understood that similar versions exist for oligonucleotide probes 3, 3', 4 and 4' wherein oligonucleotide probe 3 is similar to oligonucleotide probe 1; oligonucleotide probe 4 is similar to oligonucleotide probe 2; oligonucleotide probe 3' is similar to oligonucleotide probe 1'; and oligonucleotide probe 4' is similar to oligonucleotide probe 2';

As a matter of convenience all further descriptions will regard option 4 described above, in which oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; Oligonucleotide probe 1' has a targeting sequence

A' and a protecting sequence B'; oligonucleotide probe 2 has a targeting sequence C; and oligonucleotide probe 2' has a targeting sequence C'.

As further detailed in Figure 6, targeting sequence A of oligonucleotide probe 1 includes a long part  $\alpha$  and a short part  $\alpha'$  (the border between part  $\alpha$  and part  $\alpha'$  is denoted by a vertical line in the Figure); targeting sequence C' of oligonucleotide probe 2' includes a long part  $\gamma$  and a short part  $\gamma'$  (the border between part  $\gamma$  and part  $\gamma'$  is denoted by a vertical line in the Figure); part  $\alpha$  of targeting sequence A of oligonucleotide probe 1 and targeting sequence A' of oligonucleotide probe 1' are complementary to each other; part  $\alpha'$  of targeting sequence A of oligonucleotide probe 1 and part  $\gamma'$  of targeting sequence C' of oligonucleotide probe 2' are complementary to each other; targeting sequence C of oligonucleotide probe 2 and part  $\gamma$  of targeting sequence C' of oligonucleotide probe 2' are complementary to each other; part  $\gamma'$  of targeting sequence C' of oligonucleotide probe 2' and part  $\alpha'$  of sequence A of oligonucleotide probe 1 are complementary to each other. X and Y are chemical functionality groups, wherein X and Y groups could form a chemical bond. A similar structure characterizes oligonucleotide probes 3, 3', 4 and 4'. For simplicity, some of the descriptions herein will refer only to oligonucleotide probes 1, 2, 1', and 2' whereas these descriptions suit also oligonucleotide probes 3, 4, 3' and 4', except if noted otherwise.

As shown in the Figure 7, if a target nucleic acid sequence is present in a test sample, targeting sequence A and targeting sequence C are either entirely complementary or are sufficiently complementary to adjacent regions of the target sequence to form a stable hybrid under selected hybridization conditions. If a strand complementary to a target nucleic acid sequence is present in a test sample, targeting sequence A' and targeting sequence C' are either entirely complementary to the target complementary sequence or are sufficiently complementary to adjacent regions of the target complementary sequence to form a stable hybrid under selected hybridization conditions.

The terms "adjacent regions of a target sequence" or "adjacent regions of a target complementary sequence" as used herein refer to sequences in these nucleic acid molecules that are preferably immediately abutting and juxtaposed to one another or alternatively are separated by one or two nucleotide bases.

The term "abutting" as used herein refer to targeting sequences A and C or A' and C' which are not forming a chemical bond between their 3' end and 5' end

positions, as in the enzymatic ligation, but may form chemical bonds between the X and Y chemical functionality groups, wherein X and Y groups could form a chemical bond as will be detailed below.

5           The minimum number of nucleotides of targeting sequences A and A' and of targeting sequences C and C' of the relevant oligonucleotide probes is the smallest number that gives sufficient selectivity in the amplification and detection process of the present invention. For example, these sequences may include at least six, preferably at least twelve and more preferably at least twenty  
10 deoxyribonucleotides ribonucleotides or their analogs.

          The maximum length of targeting sequences A and A' and of targeting sequences C and C' of the relevant oligonucleotide probes is limited only by the length of the target nucleic acid sequence in the test sample. These sequences  
15 should be of sufficient length to form a stable hybrid with the target sequence, but are preferably not too long to require excessive hybridization times. Some suitable maximum lengths of these sequences are 200 nucleotides, preferably 150 nucleotides and more preferably 100 nucleotides. Some suitable lengths of these sequences are 6-100 nucleotides, preferably 10-70 nucleotides, more  
20 preferably 16-50 nucleotides and most preferably 18-30 nucleotides.

          Protecting sequences B and B', may not be, but preferably are complementary to each other. Protecting sequences B and B' are preferably not complementary to any nucleic acid sequence existing in the examined nucleic  
25 acid sample. Protecting sequences B and B' may be consisted of a random universal sequence but they may also differ in sequence from one oligonucleotide probe molecule to the other.

          Protecting sequences D and D', may not be, but preferably are  
30 complementary to each other. Protecting sequences D and D' are preferably not complementary to any nucleic acid sequence existing in the examined nucleic acid sample. Protecting sequences D and D' may be consisted of a random universal sequence but they may also differ in sequence from one oligonucleotide probe molecule to the other. In some of the applications to be  
35 described herein protecting sequences B and D and protecting sequences B' and D' may be identical.

          Protecting sequences of any oligonucleotide probe are designed so they do not hybridize to the target sequence when the targeting sequences of the

oligonucleotide probes have hybridized to the target sequence or to the target complementary sequence. Therefore, for example, protecting sequence B is unhybridized when targeting sequence A and targeting sequence C hybridize to adjacent portions of the target sequence. Likewise, protecting sequence B' is unhybridized when targeting sequence A' and targeting sequence C' hybridize to adjacent portions of the target complementary sequence. These unhybridized single-stranded sequences are used for an *in situ* detection procedure as will be emphasized herein.

The design of the oligonucleotide probes built-up is preferably made so that the reaction point between the chemical functionality groups of targeting sequences A and C, is located apart from the reaction point between the chemical functionality groups of targeting sequences A' and C'. The  $\alpha'$  part of targeting sequence A and the  $\gamma'$  part of targeting sequence C' should be long enough to avoid failure of amplification due to distortion of the tertiary structure of the hybridized sequences imposed by the chemical functionality groups themselves after the formation of a chemical bond between them. The ultimate chemical functionality groups would, therefore, be ones that distort the tertiary structure of the hybridized sequences to a permissible degree that enables the use of oligonucleotide probe complementary pairs which are of the same length, that is the length of targeting sequence A equals that of targeting sequence A' and that of targeting sequence C equals that of targeting sequence C'. In these oligonucleotide probes the nucleotide content of parts  $\alpha'$  and  $\gamma'$  equal zero.

The maximum length of an  $\alpha'$  sequence of targeting sequence A and of an  $\gamma'$  sequence of targeting sequence C' depends on the length ratio between the  $\alpha$  and the  $\alpha'$  sequences and the  $\gamma$  and the  $\gamma'$  sequences, respectively.  $\alpha'$  and  $\gamma'$  sequences which are too long might lead to the undesired formation of template independent amplification products through the formation of a stable structure of the type shown in Figure 8.

There is no length limitations regarding protecting sequences B, B', D and D'. This enables a versatile use of these sequences for detection of joined oligonucleotide products as will be described herein.

At the end of targeting sequence A, in the junction between targeting sequence A and protecting sequence B of oligonucleotide probe 1 and at the end of targeting sequence A', in the junction between targeting sequence A' and protecting sequence B' of oligonucleotide probe 1', located are chemical

functionality groups, designated as X1 and X2, respectively. To each of the targeting sequences C of oligonucleotide probe 2 and C' of oligonucleotide probe 2', attached is a chemical functionality group, designated Y1 and Y2, respectively. These chemical functionality groups are covalently attached to the sugar and/or base moieties of one of the nucleotides in each sequence. When targeting sequences A and C of oligonucleotide probes 1 and 2, respectively, or targeting sequences A' and C' of oligonucleotide probes 1' and 2', respectively, are hybridized to the target nucleic acid sequence or the target nucleic acid complementary sequence, the chemical functionality groups X1 and Y1, and X2 and Y2, respectively, react chemically to form a chemical bond that joins oligonucleotide probes 1 and 2 and oligonucleotide probes 1' and 2', respectively, to form a first and a second joined oligonucleotide products of the form shown in Figure 9. oligonucleotide probes 3 and 4 and oligonucleotide probes 3' and 4' form joined oligonucleotide products in a similar fashion.

When the target nucleic acid sequence and the target nucleic acid complementary sequence do not exist in the examined nucleic acid sample, the nucleotides to which the chemical functionality group X1 and X2 are attached and the neighboring nucleotide or nucleotides in the relevant oligonucleotide probe protect the chemical functionality groups from reacting with the Y1 and Y2 chemical functionality group on another oligonucleotide probe, respectively.

The oligonucleotide probe pairs may be synthesized chemically from the four nucleotides in whole or in part by methods known in the art. Such methods include those described by Caruthers in Science 230, 281-285 (1985) and by Beaucage, *et al.*, in Tetrahedron Letters 22, 1859-1862 (1981).

#### Template sequence

The term "template sequence" as used herein refers to nucleic acid sequence to which a plurality of oligonucleotide probe pairs or a plurality of detection oligonucleotide probes hybridize. In the first cycle of the amplification procedure as will be detailed herein, the target nucleic acid sequence and the target nucleic acid complementary sequence act as template sequences. In subsequent cycles of the amplification procedure and in the detection procedure as will be detailed herein, joined oligonucleotide products serve as template sequences as well.

### Amplification product

The term "amplification product" as used herein refers to the nucleic acid sequences which are produced from chemically joining oligonucleotide probe  
5 pairs to each other to form joined sequences;

### "Spurious amplification by-product"

The term "spurious amplification by-product" as used herein, is a product,  
10 resulting from a reaction between X and Y chemical functionality groups, leading to the joining of the oligonucleotide probes belonging to an oligonucleotide probe pair to form an joined oligonucleotide product, which is target nucleic acid sequence or target nucleic acid complementary sequence hybridization independent.

### "Proximity label"

The term "proximity label" as used herein, is one of at least two labels which interact with each other to produce a detectable signal where the  
20 proximity labels are brought together. Typically, a first proximity label is used in combination with a corresponding second proximity label in order to produce a detectable signal under conditions wherein the two proximity labels are proximate to each other.

### Chemical functionality groups

Chemical functionality groups X and Y (X = X1, X2, X3 or X4 and Y = Y1, Y2, Y3 or Y4) are pairs of atoms and/or groups that are reactive with each other (X1 with Y1; X2 with Y2; X3 with Y3; and X4 with Y4) to form chemical  
30 bonds when they are brought into close proximity with one another by hybridization of targeting sequences A and targeting sequences C to a target nucleic acid sequence, or by hybridization of targeting sequences A' and targeting sequences C' to a target nucleic acid complement sequence. The distance between pairs of chemical functionality groups (e.g. X1 and Y1) should  
35 be approximately 4A° or less and in the appropriate orientation in order for a chemical reaction between the groups to take place.

A chemical functionality group of an X1 type is attached to the base or sugar moiety of a nucleotide positioned in the junction of targeting sequence A



and protecting sequence B of oligonucleotide probe 1; an X2 type is attached to the base or sugar moiety of a nucleotide positioned in the junction of targeting sequence A' and protecting sequence B' of oligonucleotide probe 1'; an X3 type is attached to the base or sugar moiety of a nucleotide positioned in the junction of targeting sequence A and protecting sequence D of oligonucleotide probe 3; an X4 type is attached to the base or sugar moiety of a nucleotide positioned in the junction of targeting sequence A' and protecting sequence D' of oligonucleotide probe 3'; Y1 and Y2 types are attached to the end of targeting sequences C and C' of oligonucleotide probes 2 and 2', respectively; and Y3 and Y4 types are attached to the end of targeting sequences C and C' of oligonucleotide probes 4 and 4', respectively.

Chemical functionality groups X1, X2, X3 and X4 can be of a same or of a different chemical nature; and chemical functionality groups Y1, Y2, Y3 and Y4 can be of a same or of a different chemical nature, as long as the members of a chemical functionality group pair (e.g. X1 and Y1) can form a chemical bond between them when targeting sequences A and C, and, A' and C', of the relevant oligonucleotide probes are hybridized to the target nucleic acid sequence and the target nucleic acid complementary sequence, respectively.

A chemical functionality group is covalently attached to a nucleotide at a sterically tolerant site which is defined as a position on a nucleotide base or sugar moiety at which a chemical functionality group can be attached without causing significant interference with hybridization of targeting sequences A and targeting sequences C of oligonucleotide probes 1 and 3, and oligonucleotide probes 2 and 4, respectively, to the target sequences or of targeting sequences A' and targeting sequences C' of oligonucleotide probes 1' and 3', and oligonucleotide probes 2' and 4', respectively, to the target complementary sequences. Sterically tolerant sites include positions on the purine and pyrimidine bases and polyvalent heteroatoms of the base or ribose portion of a nucleotide or a nucleotide analog.

Examples of sterically tolerant sites include the methyl group attached to the C-5 position of thymidine, the amino group attached to the C-6 position of adenine or cytidine, the C-8 position of adenine or guanine, the C-2' position of the ribose ring of each type of nucleotide and the hydroxyl group attached to the C-2' position of the ribose ring of a ribonucleotide.

The modification of the purine and pyrimidine bases may, for example, be performed according to methods known in the art, such as those described by Ruth in EP 135 587. The modification of a ribonucleotide at the C-2' position of the ribose ring of the ribonucleotide may, for example, be performed according to the method described by Yamana, K. *et al.* in *Bioconjugate Chemistry* 1, 319-324 (1990).

An example of nucleotides modified with a chemical functionality group at each of the above-mentioned sterically tolerant sites is shown in Figures 10-14. Whether deoxyribonucleotides or modified deoxyribonucleotides are shown in Figures 10-14, it is understood that ribonucleotides are acceptable substitutes. A list of the designations of the modified nucleotides is provided below.

A1 represents adenine with a chemical functionality group Z replacing a hydrogen from the amino group located at the C-6 position.

A2 represents adenine with a chemical functionality group Z attached to the hydroxyl group located at the C-2' position of the ribose ring.

A3 represents adenine with chemical functionality group Z replacing the hydrogen located at the C-8 position.

A4 represents adenine with chemical functionality group Z replacing the hydroxyl located at the C-2' position of the ribose ring.

C1 represents cytidine with a chemical functionality group Z replacing a hydrogen from the amino acid group located at the C-6 position.

C2 represents cytidine with a chemical functionality group Z attached to the hydroxyl group located at the C-2' position of the ribose ring.

C3 represents cytidine with chemical functionality group Z replacing the hydroxyl group located at the C-2' position of the ribose ring.

G1 represent guanine with a chemical functionality group Z replacing the hydrogen located at the C-8 position.

G2 represents guanine with a chemical functionality group Z attached to the hydroxyl group located at the C-2' position of the ribose ring.

G3 represents guanine with chemical functionality group Z replacing the hydroxyl group located at the C-2' position of the ribose ring.

- 5 T1 represents thymidine with chemical functionality group Z replacing a hydrogen from the methyl group located at the C-5 position.

T2 represents thymidine with a chemical functionality group Z attached to the hydroxyl group located at the C-2' position of the ribose ring.

10

T3 represents thymidine with chemical functionality group Z replacing the hydroxyl group located at the C-2' position of the ribose ring.

- 15 U1 represents uridine with chemical functionality group Z replacing the hydroxyl group located at the C-2' position of the ribose ring.

U2 represents uridine with a chemical functionality group Z attached to the hydroxyl group located at the C-2' position of the ribose ring.

- 20 Z represents chemical functionality groups X1, X2, X3, X4, Y1, Y2, Y3 or Y4.

It is important to note that chemical functionality groups X and Y do not have to be attached at the same positions on their respective nucleotides. For example, without limitation, group X could be attached to uridine at position C-5 on an nucleotide in the junction of A/B sequence and group Y could be attached to position C-2' on an appropriate nucleotide in the end of targeting sequence C.

The preferred position for attaching one of the chemical functionality group, Y, for example, to a nucleotide is the C-2' position of the ribose ring of the nucleotide. For example, it is convenient to replace the hydroxyl group at the C-2' position of the ribose ring with an amino group by, for example, the protocol described in Moffatt, *et al.*, J. Org. Chem. 36, 250 (1971), or by an aminomethyl group as described by Ioannidid *et al.* Nucleosides and Nucleotides, 11: 1205 (1992), while the second chemical functionality group, X, for example, is attached, for example, to the C-5 position of the pyrimidine base. For example, see Ruth in EP 135 587. The amino group can serve either as a chemical functionality group, or as a bridging group for the attachment of chemical functionality groups to the ribose ring.

A chemical functionality group can optionally contain a bridging group through which it is attached to the nucleotide. Examples of bridging groups include, but are not limited to, amino, amido, thio, carbonyl, carboxyl, alkyl groups, aryl, alkylaryl and arylalkyl groups, optionally at any position with groups such as but not limited to amido, carbonyl, carboxyl, amino and thio. Alkyl groups may be cyclic in whole or in part. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, pentyl, cyclopentyl, hexyl, cyclohexyl, etc. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, imidazolyl, indyl, etc.

10

In a given pair of oligonucleotide probes one member of the pair has a nucleophilic chemical functionality group and the other member of the pair has an electrophilic chemical functionality group (i.e. if X is a nucleophile, then Y is an electrophile, and vice versa).

15

Some examples of nucleophiles include -SH, -NH<sub>2</sub>, -NHA (where A is an alkyl group, such as methyl, ethyl, propyl, butyl, etc. or an aryl group, such as phenyl, naphthyl, imidazolyl, indyl, etc.). Electrophiles are capable of forming single or double bonds via electron transfer from a nucleophile. The reaction between the nucleophile and the electrophile may involve the addition of the nucleophile across a double bond attached to an electron withdrawing group or the substitution of a nucleophile for an electrophilic leaving group.

20

One example of the addition of a nucleophile across a double bond is a Michael addition such as the addition of a thiol group to a double bond of a maleimido moiety.

25

Other types of reaction between the chemical functionality groups are, for example, the Diels-Alder reaction or any pericyclic reaction that produces one or more new chemical bonds.

30

The preferred embodiment for a Diels-Alder reaction is the system where uridine is modified at the C-5 position to form a Diene which functions as a chemical functionality group, X, for example in oligonucleotide probes 1, 1', 3 and 3'. Whereas in the end of targeting sequences C and C', the sugar is modified at the C-2' position by 2-butenedioic acid which functions as a chemical functionality group, Y, for example, as is illustrated in Figure 15.

35

Computer modeling of this particular example revealed that in order for Diels-Alder reaction to take place, the amino group at the C-2' position should be extended one more atom that has a tetrahedral configuration. Methylene group for example, could meet this requirement.

5

Chemical functionality groups can also be selected that form chemical bonds via a photochemical reaction such as [2 + 2] photo-cyclodimerization or other type of photocycling.

10      Protection of chemical functionality groups from being reactive with each other in the absence of the target nucleic acid sequence

One of the most important features in DNA oligonucleotide probe amplification according to the method of invention, is to eliminate spurious  
15      amplification by-products. The present invention offers versatile ways of protecting chemical functionality groups (X and Y) from being reacted with each other in a template-independent manner. In a preferred embodiment, the chemical bond between X and Y groups is formed via the Diels-Alder reaction. This reaction is preferred since it is region controlled and stereospecific by  
20      nature. For example, the  $\pi$  electrons of the Diene and the Ene groups should precisely overlap in order to interact in a pericyclic reaction.

25      Description of the chemical amplification process of the method of the invention for the detection of the presence of a nucleic acid sequence in a sample

25

In a first embodiment of the method of the present invention it is employed for the detection of the presence of a nucleic acid sequence in a sample.

30      Amplification of a target nucleic acid sequence is accomplished in the present invention by joining two or more chemically modified oligonucleotide probes for each strand of a target nucleic acid sequence, to form a joined oligonucleotide product. The "amplification" that is achieved through the methods of the present invention denotes an increase in the amount of desired  
35      nucleic acid molecules present in the reaction vessel. "Substantial amplification" refers to greater than about 100-fold amplification. Once formed, the joined oligonucleotide product serves as a template for further production of joined oligonucleotide products. The steps of the process are repeated a sufficient number of times to produce a detectable amount of joined oligonucleotide

products. Each repetition of the steps of the process of the present invention is referred to as a cycle. The number of cycles required to produce a detectable amount of joined nucleotide products depends to a great extent on the number of target molecules initially present in the examined nucleic acid sample. The greater the number of target molecules in a sample, the fewer the number of cycles needed to produce a detectable amount of joined oligonucleotide products. When a desired amount of joined oligonucleotide products is formed, it is detected. A novel aspect of the present invention is the way in which the oligonucleotide probes are joined to form an oligonucleotide product. Neither DNA polymerase nor DNA ligase is used in the present invention to form the joined oligonucleotide products.

Oligonucleotide probes 1, 1', 2, and 2' are used in the process of the present invention to amplify target sequences in a single or double-stranded nucleic acid molecule as follows.

As described above, when a target nucleic acid sequence is present in a test sample, under carefully controlled hybridization conditions, only targeting sequence A and targeting sequence C of oligonucleotide probes 1 and 2 respectively, hybridize to adjacent regions of the target sequence. This leaves protecting sequence B of oligonucleotide probe 1 unhybridized to the target sequence. When targeting sequence A and targeting sequence C have formed stable hybrid complexes with the target sequence, chemical functionality groups X1 and Y1 are brought into sufficiently close proximity to form a chemical bond. The bond between chemical functionality groups X1 and Y1 joins oligonucleotide probe 1 to oligonucleotide probe 2, forming a first joined oligonucleotide product. Once formed, the two sequences of the first joined oligonucleotide product constitute a "target complementary sequence", and are complementary to adjacent sequences of the target sequence.

Similarly, when targeting sequence A' and targeting sequence C' of oligonucleotide probes 1' and 2', respectively, hybridize to adjacent regions of the target complementary sequence, protecting sequence B' of oligonucleotide probe 1' is left unhybridized. This, in turn, brings chemical functionality group X2 of targeting sequence A' and chemical functionality group Y2 of targeting sequence C' into sufficient proximity to form a chemical bond that joins oligonucleotide probes 1' and 2' together to produce a second joined oligonucleotide product. Once formed, the two sequences of the second joined

oligonucleotide product constitute a "target sequence" and are complementary to adjacent sequences of the target complementary sequence.

5       The chemical functionality groups X1 and X2 on oligonucleotide probes 1 and 1' are sheltered, and therefore protected from interacting with chemical functionality groups Y1 and Y2, by nucleotides of the protecting sequences B and B', on one side, and by nucleotides of the targeting sequences A and A' on the other side, respectively.

10       Furthermore, the chemical functionality groups X1 and X2 on oligonucleotide probes 1 and 1' may be sheltered, and therefore protected from interacting with chemical functionality groups Y1 and Y2, by providing protecting sequences B and B' with sequences which are complementary in a  
15       palindrome manner to targeting sequences A and A', therefore creating a stem and loop structure, which stem is positioned so that the chemical functionality groups are base paired and therefore protected. Similarly, providing protecting sequences D and D' with sequences which are complementary in a palindrome  
20       manner to targeting sequences A and A' would protect chemical functionality groups X3 and X4 on oligonucleotide probes 3 and 3' from interacting with chemical functionality groups Y3 and Y4 on oligonucleotide probes 4 and 4' when they are free in solution.

25       The chemical functionality groups X1 and X2 on oligonucleotide probes 1 and 1' and the chemical functionality groups Y1 and Y2 on oligonucleotide probes 2 and 2' may be further sheltered and protected by oligonucleotides 1.1, 2.1, 1.1' and 2.1' which are complementary to oligonucleotide probes 1, 2, 1' and 2', respectively, in the region where the chemical functionality groups are located (equivalent oligonucleotides 3.1, 4.1, 3.1' and 4.1' may be used to protect chemical functionality groups X3, Y3, X4 and Y4, respectively).

30       As a result of the protection of the chemical functionality groups X1 and X2 of oligonucleotide probes 1 and 1', respectively, each chemical functionality group is prevented from reacting with a corresponding chemical functionality groups of other oligonucleotide probes. Chemical functionality groups are  
35       brought into sufficiently close proximity by hybridization of targeting sequence A and targeting sequence C of oligonucleotide probes 1 and 2, respectively, to the target nucleic acid sequence, or of targeting sequence A' and targeting sequence C' of oligonucleotide probes 1' and 2' to the target nucleic acid complementary sequence.

5 A generalized illustrations of hybridized targeting sequence A and targeting sequence C, or of targeting sequence A' and targeting sequence C' to the target nucleic acid sequence or the target nucleic acid complementary sequence, with chemical functionality groups attached to the nucleotide bases, is illustrated in Figure 16. As can be seen in the Figure, chemical functionality groups X and Y can be attached either to the C-2' position of the ribose ring or to the nucleotide base.

10 A generalized illustration of both pairs of oligonucleotide probes hybridized to a double-stranded target molecule and joined by chemical functionality groups to form a first and a second joined oligonucleotide product is shown in bolded lines in Figure 17. It is understood that in the preferred  
15 embodiments of the present invention, there is no gap between the oligonucleotide probes, although in some applications, a gap of one or two nucleotides is permissible.

In a sample containing a single-stranded target molecule, the second joined oligonucleotide product is formed after the first cycle. In order to form a  
20 second joined oligonucleotide product in the absence of a target complementary molecule, a first joined oligonucleotide product must be formed in the first cycle of the process. The first joined oligonucleotide product has the target complementary sequence and functions as a template to which oligonucleotide probes 1' and 2' hybridize. Oligonucleotide probes 1' and 2' form a second joined  
25 oligonucleotide product, having the target sequence, on the second cycle and subsequent cycles of the process.

Once the first joined oligonucleotide product is formed in the first cycle of the process, the product is separated from the target sequence by denaturation.  
30 The terms "denature" or "denaturation" as used herein refer to a reversible loss of a higher order structure and to separation of hybridized nucleic acids into single-strands, produced by physiological or non-physiological conditions, such as, for example, enzymes, pH, temperature, salt or organic solvents.

35 The second joined oligonucleotide product, once it is formed, is also separated from the target complementary sequence or first joined oligonucleotide product by denaturation. The target molecule and the first and second joined oligonucleotide products serve as templates for repeated cycles of the process.



A generalized illustration of the first cycle of the amplification process of the present invention for a double-stranded sequence is shown in Figures 18-20.

5 As illustrated in Figure 18, the first cycle in the amplification procedure of a double-stranded sequence includes hybridization of the oligonucleotide probes to the target sequence and the target complementary sequence and joining of the oligonucleotide probes via the chemical functionality groups to form joined oligonucleotide products.

10 As illustrated in Figure 19, the formation of joined oligonucleotide probes via the chemical functionality groups is followed by denaturation of the first and second joined oligonucleotide products from the target sequence and the target complementary sequences, respectively.

15 Once the first cycle of the process is completed, further amplification of the target sequence is achieved by repeated cycles of denaturation of the joined oligonucleotide products, annealing of the oligonucleotide probe pairs to the joined oligonucleotide products and formation of chemical bonds between the chemical functionality groups to produce more joined oligonucleotide products.  
20 Therefore, All cycles following the first cycle necessarily have both target sequence and target complementary sequence.

A generalized illustration of the ability of the first and second joined oligonucleotide products to act as a template for the formation of additional  
25 second and first joined oligonucleotide products, respectively, during the second and all subsequent cycles of the amplification process for a single or double-stranded target sequence is shown in figure 20.

30 Hybridization of oligonucleotide probes to the target sequence and the target complementary sequence of the first and second joined oligonucleotide products formed as described in the previous step, and joining the oligonucleotide probes to form more joined oligonucleotide products.

35 In another embodiment of the present invention, linear amplification of a target sequence or, alternatively, a target complementary sequence, if present, can be accomplished by using only probes 1 and 2 or probes 1' and 2' in the above-described process, respectively.

In a preferred embodiment of the present invention, a standard hybridization buffer, such as, for example, 30% deionized formamide in water (vol/vol), 0.54 M NaCl, 30 mM sodium phosphate (pH 7.4), 0.3 mM EDTA, 5% dextran sulfate 500K m.w. (Sigma) (w/vol) and 0.1% Triton X-100 (vol/vol), is used with oligonucleotide probes of any length from six to one hundred nucleotides. Only the temperature of denaturation and the temperature of hybridization change as the length (more accurately, the melting temperature,  $T_m$ ) of the oligonucleotide probes changes. The hybridization temperature and the denaturation temperature are both functions of the length (or  $T_m$ ) of the oligonucleotide probes.

Generally, the oligonucleotide probe pairs will be present in molar excess of about  $10^5$ - $10^{15}$ , preferably  $10^9$ - $10^{15}$ , pairs per nucleic acid target sequence or target complementary sequence. The exact amount of the pairs to be used in diagnostic purposed may not be known due to uncertainty as to the amount of the nucleic acid target in a sample. However, using an average amount of  $10^{15}$  oligonucleotide probe pairs is applicable in a typical diagnosis assay format. A large molar excess is preferred in any case to improve the efficiency of the invented process.

Since the chemical functionality groups are prohibited from reacting and joining the oligonucleotide probes together if the target hybridizing sequences of both oligonucleotide probes have not hybridized to the target sequence, formation of target-independent joined oligonucleotide product is avoided.

Description of the chemical amplification process of the method of the invention for the detection of sequence alterations

In a second embodiment of the method of the present invention it is employed for the detection of nucleotide alterations in a target nucleic acid sequence. As will shortly be described, the method of the present invention, when employed for the detection of a nucleotide alteration in a target nucleic acid sequence is sensitive enough to detect a single base alteration, such as, for example, a point mutation, e.g. a single base pair alteration.

The ability of the method of the present invention to detect sequence alterations will herein be described for the detection of a single base alteration such as a point mutation in a target nucleic acid sequence.

To this end, two sets of four oligonucleotide probes are designed. The first set is designed to amplify a wild-type sequence and includes four oligonucleotide probes designated 1, 1', 2 and 2'. These oligonucleotide probes are similar in their built-up, that is the arrangement of protecting and targeting sequences, to the ones described above, used for the detection of the presence of a target nucleic acid in a test sample. The second set of oligonucleotide probes consists of oligonucleotide probes designated 3, 3', 4 and 4'. The built-up of oligonucleotide probes 3, 3', 4 and 4' of the second oligonucleotide probes set is similar to the built-up of oligonucleotide probes 1, 1', 2 and 2' of the first oligonucleotide probes set, respectively. The sequence of oligonucleotide probes 3' and 4 of the second oligonucleotide probes set is similar to the sequence of oligonucleotide probes 1' and 2 of the first oligonucleotide probes set, respectively, whereas oligonucleotide probes 3 and 4' of the second oligonucleotide probes set differ in their sequence from oligonucleotide probes 1' and 2 of the first oligonucleotide probes set, in a position that is complementary to the sequence alteration to be determined, in the target nucleic acid sequence or the target nucleic acid complementary sequence, respectively. In these positions oligonucleotide probes 3 and 4' are fully complementary to the mutant target sequence and to the mutant target complementary sequence, respectively. Furthermore, at equivalent location on oligonucleotide probes 3, 3', 4 and 4' positioned are chemical functionality groups X3, X4, Y3 and Y4 wherein X3 and Y3 chemical functionality groups can form a chemical bond when oligonucleotide probes 3 and 4 are hybridized to the mutant target nucleic acid sequence, and X4 and Y4 chemical functionality groups can form a chemical bond when oligonucleotide probes 3' and 4' are hybridized to the mutant target nucleic acid complementary sequence. These similarities and differences among the oligonucleotide probes constituting the first and second oligonucleotide probe sets are schematically depicted in Figure 21 along with a wild-type and a mutant (A → G point mutation as read from the target nucleic acid sequence) target nucleic acid sequence and complementary sequence.

For the execution of a minute sequence alteration detection procedure according to the second embodiment of the method of the present invention in its simplest form, two reaction vessels are used. In a first reaction vessel contained are a nucleic acid sample, a suitable buffer to carry out an amplification process as described above and oligonucleotide probes of the first oligonucleotide probes set, these are oligonucleotide probes 1, 1', 2 and 2'. In a second reaction vessel contained are the nucleic acid sample, the suitable buffer and oligonucleotide probes of the second oligonucleotide probes set, these are oligonucleotide probes

3, 3', 4 and 4'. Suitable number of amplification cycles are carried out as outlined above, and, following amplification, a detection procedure is exercised to determine the presence or absence of amplification products in each of the vessels.

5

If the target nucleic acid sequence contained in the examined nucleic acid sample is homozygous for the wild-type nucleotide (A in the above given example) amplification products will accumulate only in the first reaction vessel containing oligonucleotide probes 1, 2, 1' and 2' which are complementary to the wild-type target nucleic acid sequence and to the wild-type target nucleic acid complementary sequence, at the examined nucleotide site, respectively, whereas amplification products will not accumulate in the second reaction vessel containing oligonucleotide probes 3, 4, 3' and 4' which are not complementary to the wild-type target nucleic acid sequence and to the wild-type target nucleic acid complementary sequence, at the examined nucleotide site, respectively. If, on the other hand, the target nucleic acid sequence contained in the examined nucleic acid sample is homozygous for the mutant nucleotide (G in the above given example) amplification products will accumulate only in the second reaction vessel containing oligonucleotide probes 3, 4, 3' and 4' which are complementary to the mutant target nucleic acid sequence and to the mutant target nucleic acid complementary sequence, at the examined nucleotide site, respectively, whereas amplification products will not accumulate in the first reaction vessel containing oligonucleotide probes 1, 2, 1' and 2' which are not complementary to the mutant target nucleic acid sequence and to the mutant target nucleic acid complementary sequence, at the examined nucleotide site, respectively. If the target nucleic acid sequence contained in the examined nucleic acid sample is heterozygous, that is the examined nucleic acid sample contains both the wild-type and the mutant nucleic acid sequences and their corresponding nucleic acid complementary sequence amplification products will accumulate in both reaction vessels. Therefore, if the examined nucleic acid sequence is obtained from a specific individual, the genotype of the individual (i.e. whether the individual is homozygous for the wild-type or mutant sequence or whether the individual is heterozygous) at the mutation site may thus be determined.

35

In a more sophisticated form for the execution of a minute sequence alteration detection procedure according to the second embodiment of the method of the present invention, one reaction vessel may be used provided that the amplification products derived from a wild-type sequence are

distinguishable from the amplification products derived from the mutant sequence.

When the minute sequence alteration detection procedure according to the second embodiment of the method of the present invention described above is exercised, X1, X2, X3 and X4 chemical functionality groups may all or some be identical to each other, although it is preferred that X1 and X2 chemical functionality groups are different than X3 and X4 chemical functionality groups when the reaction is performed in a single reaction vessel according to the more sophisticated form outlined above. In all cases Y1, Y2, Y3 and Y4 chemical functionality groups are selected to enable the formation of a chemical bond with the X1, X2, X3 and X4 corresponding chemical functionality groups.

In order for second embodiment of the method of the present invention to be useful at the detection of a minute sequence alteration such as a point mutation, as described above, few limitations in the built-up of the oligonucleotide probes and in the type of the chemical functionality groups should be exercised to enable a discriminative amplification described. The  $\alpha'$  parts of oligonucleotide probes 1 and 3 and the  $\gamma'$  parts of oligonucleotide probes 2' and 4' should be as short as required to impose a distortion in the tertiary structure of the hybridized sequences at the position of the chemical functionality groups even in the case of a single nucleotide mismatch. On the other hand,  $\alpha'$  parts of oligonucleotide probes 1 and 3 and the  $\gamma'$  parts of oligonucleotide probes 2' and 4' should be long enough to avoid failure of amplification due to distortion in the tertiary structure imposed by the chemical functionality groups themselves after the formation of a chemical bond between them. The chemical functionality groups should be selected to meet these specifications. The ultimate chemical functionality groups would, therefore, be ones that distort the tertiary structure of the hybridized sequences to a permissible degree that enables the use of oligonucleotide probe complementary pairs that are of the same length. As schematically presented in Figure 22, in this case, the modified nucleotides themselves (designated in the Figure T1, T2, A1, A2, C1, C2, G1 and G2, and T3, T4, A3, A4, C3, C4, G3 and G4), to which the chemical functionality groups are conjugated, act as the amplification discriminative sequences.

In another embodiment of the present invention, linear amplification of a target sequence or, alternatively, a target complementary sequence, if present,

can be accomplished by using only probes 1, 2, 3 and 4 or probes 1', 2', 3' and 4' in the above-described process.

#### Detection of amplification products

5

Once a sufficient quantity of joined oligonucleotide products is produced, it may be detected by routine methods of the art, such as, for example by immobilizing one oligonucleotide probe member of a joined oligonucleotide product (i.e. oligonucleotide probe 1 or 1') and labeling the other member (i.e. oligonucleotide probe 2 or 2') with, for example, one or more radioactive, chromogenic, chemilluminescent, or fluorescent moieties, or by sizing the joined oligonucleotide products on a gel.

Methods for labeling oligonucleotide probes have been described, for example, by Leary *et al.*, Proc. Natl. Acad. Sci. USA (1983) 80:4045; Renz and Kurz, Nucl. Acids res., (1984) 12:3435; Richardson and Gumpert, Nucl. Acids Res. (1983) 11:6167; Smith *et al.*, Nucl. Acids Res. (1985) 13:2399; and Meinkoth and Wahl, Anal. Biochem. (1984) 138:267.

The label may be radioactive. Some examples of useful radioactive labels include  $^{32}\text{P}$ ,  $^{33}\text{P}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$  and  $^3\text{H}$ . Use of radioactive labels have been described in U.K. 2,034,323, U.S. 4,358,535 and U.S. 4,302,204.

Some examples of non-radioactive labels include enzymes, chromophores, atoms and molecules detectable by electron microscopy, and metal ions detectable by their magnetic properties.

Some useful enzymatic labels include enzymes that cause a detectable change in a substrate. Some useful enzymes and their substrates (in brackets) include, for example, horseradish peroxidase (pyrogallol and o-phenylenediamine), beta-galactosidase (fluorescein beta-D-galactopyranoside) and alkaline phosphatase (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium). The use of enzymatic labels have been described in U.K. 2,019,404, EP 63,879, and by Rotman, Proc. Natl. Acad. Sci., 47, 1981-1991 (1961).

Useful chromophores include, for example, fluorescent, chemilluminescent, and bioluminmolecules, as well as dyes. Some specific

chromophores useful in the present invention include for example, fluorescein, rhodamine, Texas red, phycoerythrin, umbelliferone and luminol.

5 Detection of the joined oligonucleotide product is performed by methods known in the art, such as with a radioactive label or with a non-radioactive capture assay. For example, joined oligonucleotide products with a radioactive label are detected by autoradiography following sizing of the joined oligonucleotide products on a gel. Alternatively, joined oligonucleotide products are detected in a non-radioactive capture assay by attaching a receptor, such as, 10 for example, biotin to oligonucleotide probe 1 and attaching an enzymatic label, such as, for example, heat stable alkaline phosphatase, to oligonucleotide probe 2. A microtiter plate coated with a ligand for the receptor, such as, for example, avidin is used to capture oligonucleotide probe 1 via the biotin attached to the probe. The enzymatic label attached to oligonucleotide probe 2 is exposed to a 15 chromogenic substrate, such as 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium, for example, and a colorimetric change in the substrate is detected by, for example, measuring the optical density (O.D.) of the solution.

20 The labels may be conjugated to the oligonucleotide probe by methods that are well known in the art. The labels may be directly attached through a functional group on the oligonucleotide probe. Some examples of suitable functional groups include, for example, amino, carboxyl, sulfhydryl, melamide, isocyanate and isothiocyanate.

25 Alternatively, labels such as enzymes and chromophoric molecules may be conjugated to the oligonucleotide probe by means of coupling agents, such as dialdehydes, carbodiimides, and the like.

30 The label may also be conjugated to the oligonucleotide probe by means of a ligand attached to the oligonucleotide probe by a method described above, and a receptor for that ligand attached to the label. Any of the known ligand-receptor combinations is suitable. Some suitable ligand-receptor pairs include, for example, biotin-avidin or biotin-streptavidin, and antigen-antibody. The biotin-avidin combination is preferred.

35

If a label is used to detect the joined oligonucleotide product, label can be attached to either part or sequence of one or more of the oligonucleotide probes.

*In situ* detection of amplification products

Following a sufficient number of cycles a detectable quantity of amplification products is generated and may be detected in accordance with the detection procedures of the present invention, described above. Nevertheless, it is highly advantageous to have an effective *in situ* detection procedure(s) that enables the detection of thus formed amplification products merely by the addition of a detection reagent to the reaction vessel preferably before the amplification process is initiated or, alternatively, after the amplification process is completed.

A straight forward approach to achieve the above *in situ* detection of amplification products is to design the chemical functionality groups X1 and Y1, X2 and Y2, X3 and Y3 and/or X4 and Y4 such as they form a detectable compound when a chemical bond is formed between them.

The detectable compound may for example be detected colorimetrically in O.D. units or fluorimetrically depending on the chemical nature of the compound. The compound may also be detected via directly or indirectly labeled antibodies, for example a monoclonal antibody, raised against the compound.

*In situ* detection of amplification products may also be accomplished as delineated herein:

During the execution of the amplification procedures described above, single-stranded sequences B and B', and/or D and D', are obtained. These single-stranded sequences are unique to amplification products, therefore, one or all, may be employed to detect the presence of amplification products in accordance with two detection procedures to be described herein:

For simplicity purposes the description below refers mainly to protecting sequences B and B' of oligonucleotide probes of the first oligonucleotide probes set. It should be understood that the same description is valid also for protecting sequences D and D' of oligonucleotide probes of the second oligonucleotide probes set.

If the nucleotide sequence of protecting sequences B and B' are selected to render them complementary to each other, than after the amplification process



is completed, all B and B' protecting sequences that are not incorporated into an amplification product eventually hybridize to one another along with the targeting sequences A and A' of oligonucleotide probes 1 and 1', whereas B and B' protecting sequences that are incorporated into amplification product remain single-stranded, as depicted in thick lines in Figure 23.

In a case where protecting sequences B and B' are selected to be universal in sequence, they may be employed to detect any desired target nucleic acid sequence as will be described herein for the third and fourth embodiments of the method of the present invention.

In a third embodiment of the method of the present invention, employed are two labeled detection oligonucleotide probes in an *in situ* detection process which involves proximity energy transfer labeling. As a first detection oligonucleotide probe serve protecting sequences B and/or B' of oligonucleotide probes 1 and 1', respectively. The first detection oligonucleotide probe is conjugated to a proximity label moiety R1. A second detection oligonucleotide probe B.1 and/or B'.1 is being conjugated to a corresponding second proximity label moiety R2. As shown in Figure 24, the second detection oligonucleotide probes B.1 and B'.1 are complementary to protecting sequences B and B', respectively. In a preferred embodiment of the invention, the second detection oligonucleotide probes B.1 and B'.1 are connected directly or indirectly to form a continuous molecule B.1-B'.1, as shown in Figure 25.

The two labeled detection oligonucleotide probes hybridize to one another and therefore bring the proximity label moieties R1 and R2 to a proximity which is sufficient for their interaction to produce a detectable signal. In the case where detection oligonucleotide probes B.1 and B'.1 are each an individual molecule, hybridization of the kind shown in Figure 24 is formed, whereas, if the detection oligonucleotide probes B.1 and B'.1 are connected to form a continuous molecule B.1-B'.1 (delineated as —●— in Figure 25), hybridization leads to the formation of aggregates composed of a variable number of amplification products linked to one another via the B.1-B'.1 molecule, as shown in Figure 25, where ●●● delineate a linkage position of additional amplification products.

When the two labeled detection oligonucleotide probes, for example B and B.1, are hybridized, proximity labeling moieties R1 and R2 are brought into

proximity that enables an energy transfer reaction between them to occur, resulting in a measurable energy emission.

5 For example, the first proximity label R1 may be an energy donor and the second proximity label R2 may be an energy acceptor. For example an energy donor, such as a fluorescent or chemilluminescent compound, may be used as one proximity label, with an energy acceptor, such as rhodamine being utilized as the second proximity label.

10 The detection procedure described above is relatively simple to use in combination with the amplification procedure since all it requires is additional oligonucleotide probes (B.1 and/or B'.1 or B.1-B'.1) and one additional cycle of hybridization.

15 The second detection oligonucleotide probe, to which R2 proximity labeling moiety is attached may be added to the reaction vessel along with all other reagents, before the amplification process is started, or alternatively it may be added to the reaction vessel after the amplification process is completed.

20 If, in turn, the target nucleic acid is not included in the examined sample, no amplification occurs, all B and B' sequences are hybridized to one another along with the targeting sequences A and A' of oligonucleotide probes 1 and 1', respectively and therefore the second proximity labeling detection oligonucleotide probe do not hybridize to them and a signal is not formed.

25 If the second embodiment of the method of the present invention, which embodiment aimed at the detection of minute sequence alterations is exercised, use of different proximity labeling moieties (i.e. ones that produce a different signal when are brought to an appropriate proximity) on each of the oligonucleotide probes sets, will enable to perform the sequence discriminative amplification of the wild-type or the mutant nucleic acid sequences in a single reaction vessel, simultaneously.

35 Yet, in a fourth embodiment of the method of the present invention the *in situ* detection of the amplification products is based upon the release of a label moiety L conjugated to single-stranded B and/or B' sequences which are incorporated into amplification products, and the removal of all double-stranded B and B' sequences along with label moieties conjugated to them from the test

vessel via an affinity separation moiety S conjugated to oligonucleotide probes 1 and/or 1'.

As explained above, after the amplification process is completed, protecting sequences B and B' which are incorporated into amplification products are the sole B and B' single-stranded sequences in the reaction vessel, since protecting sequences B and B' of oligonucleotide probes 1 and 1' that were not incorporated into an amplification product are hybridized to one another as shown above. These single-stranded B and B' sequences may be nucleated, for example, via the use of a single-stranded specific nuclease, or an appropriate chemical process, resulting in the release of the label moiety L conjugated to them to the surrounding solution.

To one or more locations of one or more of the oligonucleotide probes used in the amplification reaction of the method of invention, these are, for example, various locations along the targeting sequences A and A' of oligonucleotide probes 1 and 1', respectively, conjugated is one or more affinity separation moiety S. The affinity separation moiety S is characterized by its ability to bind a counterpart moiety S' in high affinity. The affinity separation moiety S may for example be a hapten or a biotin and the counterpart moiety may, therefore, be a suitable antibody or, avidin or streptavidin, respectively. The counterpart affinity separation moiety S' is preferably attached to a solid support such as for example plastic, dextran, glass or magnetic beads or preferably to the top of the reaction vessel, for example to a screw cap.

Following amplification, a single-strand specific nuclease, such as, for example, Exonuclease VII, from *E. coli*. which is a processive single-stranded exonuclease that acts from both the 3' and 5' ends of single-stranded DNA and is, therefore, a suitable nuclease to carry out the above function (See, e.g. Berk A.J. *et al* Cell 12:721-732 (1977) and Goff S. *et al*, Proc. Natl. Sci. USA 75:1763-1767 (1978)), is added to the reaction vessel along with an appropriate buffer. Alternatively, a suitable chemical process aimed at the specific degradation of single stranded sequences is employed. The mixture is incubated at the appropriate conditions (for example at 37°C for 30 minutes if a nuclease is used) to degrade single-stranded sequences B and B' which are incorporated to amplification products. B and B' sequences which are not incorporated to amplification products are hybridized to one another along with the A and A' targeting sequences of oligonucleotides 1 and 1', respectively, and, therefore, are not nucleated, for example, by the nuclease. The result of the nucleolysis is the

release of the label moiety L to the solution, in an amount which is proportional to the level of amplification. The result of the nucleolysis is illustrated in Figure 26. Label moieties L that were not thus released, these are label moieties conjugated to sequences B or B' that were not incorporated into amplification products, are removed by affinity separation, for example by rotating the reaction vessel by 180°, leading to the adsorption of the separation moiety S, such as biotin, to the screw cap coated with an affinity separation counterpart molecule S', such as avidin in the given example. The released label moiety L, such as for example fluorescein, may thus be, fluorimetrically in the given example, detected. In a preferred embodiment, the counterpart moiety S' is attached to magnetic beads which may be removed from the reaction via rotating the reaction vessel by 180°, leading to the adsorption of the beads to the magnet embedded in the vessels cap as illustrated in Figure 27.

If, in turn, the target nucleic acid is not included in the examined sample, no amplification occurs, all B and B' sequences are hybridized to one another, no release of detectable label moiety L occurs upon the addition of the single-strand specific nuclease and, therefore, no label is detected in the reaction vessel after the adsorption of the affinity separation moieties to a solid support.

For simplicity purposes the amplification and detection procedures described above refer to the amplification and detection of a single target nucleic acid it should be understood that more oligonucleotide probes per sampled nucleic acid can be employed in the process of the present invention to detect various target nucleic acid sequences or sequence alterations and, as noted above, to detect a sequence alteration using one reaction vessel. Joined oligonucleotide products from different sequences of the same sampled nucleic acid can be distinguished from one another, for example, by using different labels, detection methods, or oligonucleotide probes of distinctively different lengths. It should also be understood that each target nucleic acid sequence may be tested by two sets of oligonucleotide probes. In this case, the detection is monitored twice as a double check.

#### Advantages of the method of the present invention as compared with prior art

Methods according to preferred embodiments of the present invention enjoy a number of advantages relative to methods of prior art aimed at nucleic acid amplification and detection of sequence variations.

As far as the enzyme-based methods such as allele specific oligonucleotide probe (ASO) hybridization; reverse-ASO; restriction site generating PCR (RG-PCR); denaturing/temperature gradient gel electrophoresis (D/TGGE); single-strand conformation polymorphism (SSCP); heteroduplex analysis; restriction fragment length polymorphism (RFLP); PCR restriction fragment length polymorphism (PCR-RFLP); nuclease protection assays; chemical cleavage and other, less frequently used, methods are concerned, the method of the present invention acts as an enzyme-free system for selective amplification of target nucleic acid sequences and enjoys a number of advantages:

First, The method of the present invention do not require highly skilled personnel for (a) accurate execution of the amplification and detection procedures which include one to two simple steps and do not involve complicated steps such as gel electrophoresis and/or complicated blotting and hybridization procedures, and (b) for interpreting the results;

Second, strict calibration steps are not required before the examination of any new DNA alteration;

Third, theoretically, the method of the present invention is suitable for the detection of all sequence alterations;

Fourth, the method of the present invention is easy to automate;

Fifth, the method of the present invention is not based upon the use of enzymes such as DNA and RNA polymerases, restriction endonucleases single-strand-specific endo- and exonucleases and the like, which in addition to being expensive, exhibit lot-to-lot variations in activity and in the concentration of undesired nuclease contaminants.

As far as the chemical amplification reaction (CAR) (international PCT application US 94/06690) is concerned:

First, as explained above, the CAR method has a major drawback since a cross-like structure (shown in Figure 3) of a high thermodynamic stability may form, and upon amplification may result in a template independent false-positive amplification product. The oligonucleotide probes built-up of the methods of the present invention was carefully designed to avoid the formation of target nucleic

acid sequence independent stable hybridization structures such as the one shown in Figure 3. Nevertheless, protecting sequences implemented in the present invention are not limited by their length. This characteristic became advantageous for the detection procedures described above.

5  
Second, the method of the present invention is fully capable of discriminative amplification of sequences differing by a minute sequence alteration such as a point mutation, whereas the CAR method is incompetent in discriminating between target nucleic acid sequences which differ by minute  
10 sequence alterations. Therefore, the method of the present invention is suitable for analysis of mutations associated with various genetic diseases as well as detecting the presence of any target nucleic acid sequence in a sample including those of pathogens. The ability of the method of the present invention to detect point mutations is due to the positioning of the chemical functionality groups  
15 close to the examined site of the target nucleic acid sequence, that is in the junction between targeting sequences A and A' and protecting sequences B or D and B' or D', respectively, and in the end of targeting sequences C and C'. The positioning of the chemical functionality groups in the CAR method is away from the target nucleic acid sequence, therefore, this method is not sensitive  
20 enough to discriminate between sequences which differ by a minute sequence alteration such as a point mutation.

Third, in some of the preferred embodiments of the method of the present invention all reagents required for the amplification and the detection processes  
25 are included in the test vessel prior to amplification. Therefore, the present invention is particularly advantageous because of its unique ability to generate a positive or a negative signal without the need to open the test vessel. The simplicity of the detection process is due to the formation of single-stranded protecting sequences B and B' and/or D and D' which are unique to amplification  
30 products generated by the method of the present invention.

A method according to the present invention can be used to determine the identity of nucleotide bases at different alleles each of a specific position in nucleic acids of interest via the procedure as described above

35

A method according to the present invention can also be used to type a sample containing nucleic acids. Such a process includes identifying the nucleotide base or bases at each of one or more specific positions, each such

nucleotide base being identified using different oligonucleotide probe sets as described above.

5 A method according to the present invention can be further used to identify different alleles in a sample containing nucleic acids. Such a process includes identifying the nucleotide base or bases present at each of one or more specific positions, each of such nucleotide bases being identified by the method described above.

10 Another application of a method according to the present invention is in the determination of the genotype of an organism at one or more particular genetic loci. Such a process calls for obtaining from the organism a sample containing genomic, mitochondrial or chloroplast DNA or RNA. The nucleotide  
15 base or bases present at each of one or more specific positions in nucleic acids of interest is identified by the process described above. In this way, different alleles are identified and, in turn, the genotype of the organism is determined at one or more particular genetic loci.

20 The subject invention also provides a method of typing a sample of nucleic acids which consists of identifying the base or bases present at each of one or more specific positions, all such nucleotide bases being identified using the method as outlined above, where each specific position in the nucleic acids of interest is determined using different oligonucleotide probe sets. The identity of each nucleotide base or bases at each position can be determined individually  
25 or, preferably, the identities of the nucleotide bases at different positions can be determined simultaneously using for example different label moieties.

The subject invention also provides another method of typing a sample of nucleic acids which comprises determining the presence or absence of one or  
30 more particular nucleotide sequences as outlined above.

The subject invention also provides an additional method of typing a sample containing nucleic acids. First, the presence or absence of one or more particular nucleotide sequences is determined as outline above. Second, the  
35 nucleotide base or bases present at each of one or more specific positions is identified as outlined above.

The subject invention further provides a method for identifying different alleles in a sample containing nucleic acids which comprises identifying the base or bases present at each of one or more specific positions as outlined above.

5       Sets of oligonucleotide probes as described above can be used under appropriate hybridization conditions as a kit for diagnosing or typing nucleic acids. The kit further includes the appropriate reagents aimed at the detection of amplification products as outlined above, and suitable buffers, such as an hybridization solution.

10

      Table I lists a sampling of the various diseases which are known to result from the presence of one or more mutations in a gene encoding a specific protein or enzyme. Most of these diseases are recessive diseases, i.e., the diseased individual has both alleles carrying a mutation, the mutation resulting in the  
15   protein being absent (gene not expressed); being in an inactive state (having an altered amino acid sequence); or being present in less than the required amounts (significantly reduced gene expression).



**TABLE I**

|    | <b><u>DISEASE</u></b>  | <b><u>GENE</u></b>            |
|----|--|-------------------------------|
| 5  | Hemophilia A   | factor VIII                   |
|    | Hemophilia B   | factor IX                     |
|    | Lesch-Nyhan syndrome   | HPRT                          |
| 10 | Ornithine transcarbamylase   | OTC                           |
|    | Hereditary Amyloidosis (HA)  | transthyretin (TTR)           |
|    | Gaucher  | glucocerebrosidase            |
| 15 | Cystic Fibrosis  | CFTR                          |
|    | Osteogenesis imperfecta  | collagen (I, II), procollagen |
| 20 | Hemoglobinopathies<br>(e.g., $\beta$ -thalassemia, Sickle cell anemia) | hemoglobin genes              |
|    | Acute intermittent porphyria (AIP)                                     | uroporphyrinogen I synthetase |
| 25 | Phenylketonuria  | phenylalanine hydroxylase     |
|    | Tay Sachs  | hexosaminidase A (HEXA)       |
|    | Familial hypercholesterolemia (FH)                                     | LDL receptor                  |
| 30 | Neurofibromatosis  | NF1                           |

35 The ongoing research to determine the genetic basis for diseases and the  
 advent of technologies such as the polymerase chain reaction (PCR) has resulted  
 in the discovery and complete sequencing of more and more genes encoding  
 structural protein or enzyme products, a mutation in which would lead to either  
 no expression of the gene product or expression of a product which is  
 qualitatively or quantitatively impaired and thereby resulting in a disease. There

is thus an ever expanding field of application of the above method of the invention.

5 The method of the invention, besides having use in diagnosis of specific disease linked mutations in known gene regions, may also be of use in testing for the presence of a specific sequences associate with blood typing, tissue classification - HLA-typing, sex determination or possible susceptibility of an individual to certain diseases. Tissue classifications, for example, may be determined by identifying polymorphism being specific for a particular individual. Screening these known HLA gene sequences by the present method  
10 may also be used as a diagnostic tool to determine whether the individuals in question are susceptible to certain diseases, e.g., various specific autoimmune diseases, which are correlated with the specific HLA genes carried by the individual.

15

As noted above, the method of the invention may also be applied in the field of forensic medicine in which polymorphism in specific genes, e.g., the  $\beta$ -globin gene cluster and the various known repeat sequences, can be determined in, for example, blood or semen samples obtained at the scene of a crime and the  
20 results used to indicate whether or not a particular suspect was involved in the crime. Similarly, the aforesaid determination may also be used to determine whether a certain male individual is the father in cases of disputed paternity.

25 There is evidence that certain cancers may be the result of specific point mutation in the sequence of certain genes and, accordingly, the present methods may be used as an early diagnostic tool to screen the general population or those individuals considered most likely to develop such cancers.

30 Another application of the present methods, as noted above, is the detection of microorganisms in a sample on the basis of the presence of specific sequences in the sample. For example, an individual suspected of being infected by a microorganism, such as a bacteria or virus, can be tested by using a combination of oligonucleotide probes which anneal only with a specific bacterial and/or viral DNA sequences and not with sequences present in the individual. One example of such an application is in the screening of individuals  
35 for the presence of the AIDS virus. Similarly, different species or strains of bacteria in a sample may be distinguished one from the other, e.g., the presence of Shigella vs. Salmonella bacteria which are difficult to distinguish from one another by standard techniques.

Gene regions corresponding to all of those set forth in Table I above and many others, may be analyzed for the presence of one or more point or other mutations at any number of sites within the gene region, or the existence of polymorphism for any specific allele, or whether the individual being tested is homozygous for a specific mutation, heterozygous therefor (i.e. carrier) or whether the individual is normal at this specific location (i.e. carrying two normal alleles).

The present method can be a very effective alternative for the traditional mutation detection methods which use radioactive material, different hybridization or PCR conditions for every mutation, specific gels or an expensive automated sequencer. The present method enables a large scale diagnostic procedure with the possibility of screening many different samples in a short period of time. Furthermore, the present method provides a means for population screening for a wide range of inherited diseases and genetic disorders such as genetic cancers and the like, and can also be easily adapted for screening polymorphism such as those in HLA genes, or detecting for the presence of pathogenic RNA or DNA, or the differentiation among different strains of bacteria or viruses.

The invention will now be further illustrated by the following examples:

EXAMPLE 1

5

The use of the amplification and the detection methods of the present invention to amplify and detect a 54 base pair DNA sequence contained in the Human Papilloma Virus type 16 genome.

10

The region to be amplified and detected is a double-stranded sequence which spans nucleotide base numbers 800 to 854 (numbers according to Seedorf, K., *et al.*, Virology 145, 181-185 (1985)) of the Human Papilloma Virus type 16 (HPV-16) genome, having the sequence (SEQ. ID. NO. 1):

15

5'- AGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACC-3'  
3'- TCTGGACAATTACCCGTGTGATCCTTAACACACGGGGTAGACAAGAGTCTTTGG-5'

20

Four oligonucleotide probes, designated 1, 1', 2 and 2', are used to amplify the above target sequence, which oligonucleotide probes have the following sequences:

X1  
targeting Seq. A      |      protecting Seq. B

Probe 1

25 3'-TCTGGACAATTACCCGTGTGATCCTU/AGGATGGG-5' (SEQ. ID. NO. 2)

targeting Seq. C

Probe 2

3'-Y1-UAACACACGGGGTAGACAAGAGTCTTTGG-5'  
(SEQ. ID. NO. 3)

30

targeting Seq. A'      protecting Seq. B'

Probe 1'

5'-AGACCTGTTAATGGGCACACTAGGA AU/CCTACCC-3'  
(SEQ. ID. NO. 4)

35

X2

targeting Seq. C'

Probe 2'

5'-Y2-UGTGTGCCCCATCTGTTCTCAGAAACC-3'  
(SEQ. ID. NO. 5)

The backslash lines merely depict the demarcation between targeting sequences A and A' and protecting sequences B and B' of oligonucleotide probes 1 and 1', respectively. The single vertical lines indicate a chemical bond that  
5 attaches chemical functionality groups X1 and X2 to a substituent group on uridine residues which are located at the end of targeting sequence A and A', between the junctions of targeting sequences A and A' and protecting sequences B and B' of oligonucleotide probes 1 and 1', respectively.

10 In this example a Diels-Alder reaction between X and Y chemical functionality groups is illustrated. Furthermore, in this example X1 and X2 chemical functionality groups are the same so as Y1 and Y2 chemical functionality groups, therefore, they shall be referred to as X and Y chemical functionality groups in this example.

15 As can be seen in the above listed oligonucleotide probes, X and Y chemical functionality groups are attached to uridine residues. Y groups, which serve as dienophiles in the Diels-Alder reaction, are each attached to a 2' aminomethyl uridine via the C-2' position of the ribose moiety, whereas X  
20 groups which serve as dienes are each attached to the C-5 position of the uridine base moiety.

Synthesis of 2'-trifluoroacetamidomethyluridine phosphoramidite derivative for the attachment of Y groups to probes 2 and 2' via a 2' position of a  
25 uridine residue.

A uridine residue is modified so that a desired chemical functionality group can later be covalently attached to it, after which conventional methods are used to synthesize the oligonucleotide probes in a stepwise manner and the  
30 modified uridine is positioned in any desired location. Once the oligonucleotide probes are synthesized, Y chemical functionality groups are attached to the modified uridine residues. In this example, Y chemical functionality groups of probes 2 and 2', are a 2-butenedioic acid derivative.

35 1. Synthesis of 2'-deoxy-2'-C-trifluoroacetamidomethyluridine.

The nucleoside 2'-deoxy-2'-C-azidomethyluridine may be prepared according to procedure described in Ioannidis *et al*, Nucleosides & Nucleotides, 11: 1205 (1992). Thus, a solution containing 10 mmoles azido compound (2.83

grams) in methanol (200 ml) is prepared and is vigorously stirred in a hydrogen atmosphere with 10% palladium-on-carbon catalyst (1.4 grams) for 60 minutes. The mixture is filtered and evaporated, and the aminomethyluridine is left as an oily crude. The aminoproduct, thus prepared, is employed in the following step 2 without further purification.

To a solution (50 ml) containing 10 mmoles C-2'-aminomethyluridine (2.5 grams) and 10 mmoles of triethylamine (1.1 grams) in ethylacetate which is cooled to 0°C, a solution containing 11 mmoles trifluoroacetic anhydride (2.31 grams) in Ethyl acetate (30 ml) is added dropwise. The mixture is stirred for 3 hours and then extraction with ethylacetate-water is performed. The organic layer is washed with brine and dried with anhydrous sodium sulphate. The solvent is evaporated to dryness. For further purification the product may be separated on a silica-gel column.

2. Preparation of 5'-dimethoxytrityl-2'-C-trifluoroacetamido-methyluridine.

A solution containing 10 mmoles 4,4'-dimethoxytrityl chloride (3.38 grams) in dry pyridine is added dropwise to a cooled (0°C) solution of dry pyridine (100 ml) containing 10 mmoles trifluoroacetamidouridine (3.54 grams). The mixture is stirred for 3 hours, and the pyridine is evaporated to dryness. The oily product is dissolved in ethylacetate and washed with water, brine, and the organic layer is dried with anhydrous sodium sulfate. The mixture is evaporated to dryness, and the product may be further purified on a silica-gel column.

3. Preparation of 5'-dimethoxytrityl-3'-(2-cyanoethyl N,N-diisopropyl) phosphoramidite-2'-C-trifluoroacetamido-methyluridine.

Ten mmoles of 5'-dimethoxytrityl-2'-C-trifluoroacetamido-methyluridine (6.56 grams) and 20 mmoles of N,N-diisopropylethylamine (2.60 grams) are dissolved in dry dichloromethane (50 ml) under Argon, and the solution is kept at 0°C. To this solution, 10 mmoles of 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (Aldrich) (2.36 grams) in 25 ml of dry dichloromethane is added dropwise. The reaction is stirred for 10 minutes, and kept at room temperature for 10 more minutes. Ethyl acetate (250 ml) is added to the mixture, and is extracted three times with brine. The solvent is removed

under vacuum, toluene (50 ml) is added, and the mixture is lyophilized, leaving white powder which is collected under Argon.

5 Derivatization of uridine at C-5 position for the attachment of X chemical functionality groups to probes 1 and 1' via uridine phosphoramidite derivative.

10 In this example, X chemical functionality groups of probes 1 and 1', are each a diene which is derived from the attachment of a double bond C=C to the C-5 position of a uridine base. Several dienes could be attached. The attachment of a double bond to the C-5 position of uridine is described by Bergström *et al.*, in J. Amer. Chem. Soc., 100 :8106 (1977). The preferred example is the attachment of propylene to the C-5 position according to this reference.

15 The preparation of the 5'-dimethoxytrityl-C-5-propylene-3'-(2-cyanoethyl N,N-diisopropyl) phosphoramidite is accomplished according to Ruth J.R. *et al* in DNA 4: 93, (1985) and EP 135 587, and as described above.

20 All of the oligonucleotides listed above are synthesized and purified by the following procedure.

1. Automated Synthesis Procedures.

25 2-cyanoethyl phosphoramidites are purchased from Applied Biosystems Inc. The automated synthesis procedure includes condensation of nucleoside phosphoramidites to 30 mg of a nucleoside-derivatized controlled pore glass (CPG) bead support (500 Angstrom pore diameter), using type 380B-02DNA synthesizer from Applied Biosystems Inc. The cycles (30 minutes each) include detritylation with 2% trichloroacetic acid in dichloromethane; condensation  
30 using tetrazol as an activating proton donor; capping with acetic anhydride and dimethylaminopyridine; detritylation using 2% trichloroacetic acid in dichloromethane; and oxidation of the phosphite to the phosphate with 0.1 M I<sub>2</sub>/H<sub>2</sub>O/lutidine/tetrahydrofuran. Yields at each step are essentially quantitative and are monitored by collecting the dimethoxytrityl alcohol released during  
35 detritylation and examining it spectroscopically.

Oligodeoxyribonucleotide Deprotection and Purification Procedures.

The solid support is removed from the column and exposed to 1 ml concentrated ammonium hydroxide for 16 hours at 60°C in a closed tube. Ammonia is removed and the residue is applied to a preparative 12% polyacrylamide gel containing 7 M urea using a Tris-borate-EDTA (TBE) buffer (pH 8.0). Electrophoresis is carried out at 20 volts/cm for 5 hours, after which the band containing the product is identified by UV shadowing of a fluorescent plate. The band is excised and eluted with 1 ml double distilled water overnight at room temperature. This solution is filtered and the supernatant is extracted (3 x 300 microliter) with n-butanol. The aqueous phase is placed on top of a Sephadex G50 column (Pharmacia) (1 x 10 cm) and is eluted with double distilled water. The eluate is monitored by UV absorbance at 260 nm and the appropriate fractions are collected, quantified by UV absorbance in a fixed volume and evaporated to dryness at room temperature in a vacuum centrifuge.

Reaction of maleic anhydride with aminomethyl groups attached to uridine residues to prepare the Y chemical functionality groups of probes 2 and 2'.

Aliquots of oligonucleotide probes 2 and 2' containing 2'-aminomethyl-2'-deoxyuridine having an optical density of 5.0 (5.0 O.D.) are lyophilized to dryness each in a 1.5 ml disposable eppendorf tubes. Each probe preparation is reconstituted in 200 µl of 1 M sodium borate buffer (pH 9.3). To attach Y chemical functionality groups, 200 µl solution of maleic anhydride (Aldrich) dissolved in dimethyl sulfoxide (DMSO) at a concentration of 20 mg/ml is added to each of the vials which are then agitated at room temperature (RT) for approximately 12 hours. Each of the mixtures is then desalted and purified from excess chemical functionality group reagent via centrifugation through a Pharmacia Sephadex NAP-10 column. Each of the resulting solutions is purified on a Sephadex G50 column (Pharmacia) (1 x 10 cm). Each eluate is monitored by UV absorbance at 260 nm and the appropriate fractions are collected and are quantified by UV absorbance in a fixed volume. Each of the probes, 2 and 2', is lyophilized to dryness and stored at 4°C until used.

Amplification

The HPV-16 sequence is, for example, contained in a plasmid which is prepared by cloning the HPV-16 sequence published by Seedorf *et al.*, in



Virology 145, 181-185 (1985) in a blue script vector (Stratagene) and is dissolved in double distilled water at a concentration of 20 ng/ml.

5 The amplification procedure of the HPV-16 sequence shown above (SEQ. ID. NO. 1) according to the method of invention involves the following steps:

10  $10^{11}$  molecules of each of the oligonucleotide probes (1, 1', 2 and 2') are reconstituted in hybridization buffer at a final volume of 100  $\mu$ l. The hybridization buffer contains 30% deionized formamide in water (vol/vol)(optional), 0.54 M NaCl, 30 mM sodium phosphate (pH 7.4), 0.3 mM EDTA, 5% dextran sulfate 500K m.w. (Sigma)(w/vol) and 0.1% Triton X-100.

15 To an eppendorf tube (Perkin Elmer), containing a 1  $\mu$ l sample of the HPV-16 target sequence described above, 99  $\mu$ l of the hybridization buffer containing the four oligonucleotide probes, 1, 1', 2, and 2', is added. A second tube, which serves as control, contains all reagents but the target sequence in a final volume of 100  $\mu$ l. The solution in each of the tubes is gently vortexed. 100  $\mu$ l of mineral oil is added to each of the tubes, to prevent evaporation during  
20 the repeated heating cycles of the amplification reaction.


The tubes are placed in a DNA thermal cycler (Perkin Elmer, Cetus) and are subjected to 30 heating and cooling cycles. Each cycle consists of a 65 second incubation at 90°C and a 240 second incubation at 40°C.

25 After cycling, 20  $\mu$ l of each solution is mixed with 2  $\mu$ l of 40% glycerol in 1 x TBE (pH 8.0) containing bromphenol blue dye and is electrophorased on a 12% polyacrylamide gel using 1 x TBE buffer (pH 8.0) at 20 volts/cm for three hours, after which the gel is immersed in a 100 ml solution of ethidium bromide  
30 (0.5 mg/ml in H<sub>2</sub>O), for 45 minutes at room temperature.

The gel is exposed to Polaroid photographic film, type 57 or 667 (ASA 3000) for 0.5 second at f8, under an efficient ultra-violet (UV) light source (72,500 mW/cm<sup>2</sup>) and a band of joined oligonucleotide products in an amount as  
35 small as 10 ng may thus be detected.

EXAMPLE 2In situ nonradioactive detection of the amplified products using Exonuclease VII

5 For the *in situ* nonradioactive detection of the amplified products using Exonuclease VII oligonucleotide probes 2 and 2' are used as in Example 1 whereas to the 5'-end of oligonucleotide probe 1 attached is a Fluorescein molecule and to the 5'-end of oligonucleotide probe 1' a biotin molecule is  
10 attached, as shown below:



25 In order to attach fluorescein and biotin to the 5' end of oligonucleotide probes 1 and 1', respectively, the reagents fluorescein phosphoramidite and biotin phosphoramidite (Glenn Research) are used, respectively.

30 The oligonucleotide probes synthesis and purification is accomplished as exemplified in example 1.

For amplification, a reaction tube is constructed as follows:

35 A plastic transparent tube which is divided to two compartments separated by a destructible separation, which compartments are situated one on top of the other, is used, wherein the internal separation is coated with avidin (Sigma) on the side facing the lower compartment. The lower compartment contains the reaction mixture whereas the upper compartment contains 0.4 units of Exonuclease VII in a buffer which consists of 70 mM Tris.Cl, pH 8.0; 8 mM EDTA; 10 mM  $\beta$ -mercaptoethanol; and 50  $\mu$ g/ml BSA.

Following amplification, the reaction tube is kept at 37°C, and the content of the upper compartment is squeezed out through the destructible separation to

mix with the content of the lower compartment containing the amplification products. The reaction mixture is incubated for 30 minutes, to cleave single-stranded B and B' protecting sequences.

- 5 After the Exonuclease VII treatment, the reaction tube is rotated at 180°, and is kept at the upside down position for 10 minutes to allow the capture of biotinylated double-stranded DNA to the avidin coated cap. The reaction tube is re-rotated at 180°, and the fluorescein released to the solution from single-stranded B fragment, via the nuclease activity, is detected by a fluorometer  
10 (Perkin Elmer).

### EXAMPLE 3

- 15 The use of the amplification and the detection methods of the present invention to detect the codon 245 (GGC → GAC) point mutation of the human *p53* gene.

- Two oligonucleotide probe sets are designed to amplify an 58 bp fragment of the human *p53* gene. The first oligonucleotide probes set is designed to  
20 amplify the wild-type sequence of the gene which have the following sequence (SEQ. ID. NO. 6):

5'-TACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCA-3'  
3'-ATGTACACATTGTCAAGGACGTACCCGCCGTACTTGGCCTCCGGGTAGGAGTGGTAGT-5'  
25

The second oligonucleotide probes set is designed to amplify the mutant sequence of the gene which have the following sequence (SEQ. ID. NO. 7):

5'-TACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCA-3'  
30 3'-ATGTACACATTGTCAAGGACGTACCCGCTGTACTTGGCCTCCGGGTAGGAGTGGTAGT-5'

Oligonucleotide probes of the first set includes:

35 targeting Seq. A | protecting Seq. B  
probe 1 3'-ATGTACACATTGTCAAGGACGTACCCGCC/CGGAATCATC-flourescein-5'  
(SEQ. ID. NO. 8)

targeting Seq. C

probe 2 5'-TGATGGTGAGGATGGGCCTCCGGTTCATG-Y1-3'  
(SEQ. ID. NO. 9)

X2

5

targeting Seq. A' | protecting Seq. B'

probe 1' 5'-TACATGTGTAAACAGTTCCTGCATGGGCGG/GCCTTAGTAG-3'  
(SEQ. ID. NO. 10)

targeting Seq. C

10 probe 2' 3'-ACTACCACTCCTACCCGGAGGCCAAGTAC-Y2-5'  
(SEQ. ID. NO. 11)

The detection method for the wild-type sequence amplified using the first oligonucleotide probes set is proximity energy transfer labeling. As a first detection oligonucleotide probe serve protecting sequence B of oligonucleotide  
15 probe 1. The first detection oligonucleotide probe is conjugated to a fluorescein proximity label. A second detection oligonucleotide probe B.1 (shown below; SEQ. ID. NO. 12) is being conjugated to a corresponding second rhodamine proximity label moiety. The two labeled detection oligonucleotide probes hybridize to one another and therefore bring the proximity label moieties  
20 fluorescein and rhodamine to a proximity which is sufficient for their interaction to produce a detectable signal. When the two labeled detection oligonucleotide probes are hybridized, proximity labeling moieties fluorescein and rhodamine are brought into proximity that enables an energy transfer reaction between them to occur, resulting in a measurable energy emission which may be measured  
25 fluorometrically (excitation 472 nm, readout 577 nm).

probe B.1 5'-GCCTTAGTAG-3'

|  
rhodamine

30 (SEQ. ID. NO. 12)

Oligonucleotide probes of the second set includes:

X3

35

targeting Seq. A | protecting Seq. D

probe 3 3'-ATGTACACATTGTCAAGGACGTACCCGCT/ATCGATAACG-Isolumin 1-5'  
(SEQ. ID. NO. 13)

targeting Seq. C

probe 4 5'-Biotin-TGATGGTGAGGATGGGCCTCCGGTTCATG-Y3-3'  
(SEQ. ID. NO. 14)

X4

5 targeting Seq. A' | protecting Seq. D'  
probe 3' 5'-TACATGTGTAACAGTTCCTGCATGGGCAG/TAGCTATTGC-3'  
(SEQ. ID. NO. 15)

targeting Seq. C

10 probe 4' 3'-ACTACCACTCCTACCCGGAGGCCAAGTAC-Y4-5'  
(SEQ. ID. NO. 16)

The detection method for the mutant sequence amplified using the second oligonucleotide probes set is based upon the release of a Isoluminol label moiety conjugated to single-stranded D sequence which is incorporated into  
15 amplification products, and the removal of all double-stranded D sequences along with the Isoluminol label moieties conjugated to them from the test vessel via an affinity separation moiety biotin conjugated to oligonucleotide probe 4. The single-stranded D sequence is nucleated post amplification via the  
20 nucleolytic activity of Exonuclease VII from *E. coli*, which is a single-stranded specific nuclease. This results in the release of the Isoluminol label moiety conjugated to single-stranded D sequences, to the surrounding solution. Isoluminol label moieties that were not thus released, these are label moieties  
25 conjugated to sequences D that were not incorporated into amplification products, are removed by affinity separation. The released Isoluminol label moieties may thus be detected luminometrically.

The oligonucleotide probes synthesis and purification is accomplished essentially as exemplified in example 1.

30 The experiment described under this example is aimed at the determination of the genotype at codon 245 of the *p53* gene of an examined individual, and is based on a simultaneous amplification procedure, combined with a simultaneous detection procedure of both the wild-type and the mutant sequences, which of which exist in the examined individuals genomic DNA is to  
35 be determined.

For the combined amplification and detection reactions, tubes are constructed as follows:

Transparent tubes which have a magnet embedded in their caps, as is described in Figure 27, are used as containers for the experimental and control amplification reactions which are performed essentially as described under Example 1, except for the use of two oligonucleotide probe sets in each tube in  
5 this Example, whereas only one set is employed under Example 1.

The experimental tube contains genomic DNA obtained from an individual whose genotype is to be determined. As controls to this combined amplification and detection procedures, four additional similar tubes are  
10 employed. The first contains no target DNA sequence and therefore serve as a negative control and should result in no signal obtained by either of the detection methods. The second contains genomic DNA from an individual previously shown to be homozygous to the wild-type allele and therefore serve as a positive control for the first detection method and as a negative control to the second  
15 detection method and should result in a detectable signal of the first but not the second detection method. The third contains genomic DNA from an individual previously shown to be homozygous to the mutant allele and therefore serve as a positive control for the second detection method and as a negative control to the first detection method and should result in a detectable signal of the second but  
20 not the first detection method. The fourth contains genomic DNA from an individual previously shown to be heterozygous to the wild-type and the mutant alleles and therefore serve as a positive control for the first and second detection method and should result in a detectable signal of the first and the second detection methods.

25  
Following amplification the second detection oligonucleotide probe B.1, described above, is added to the reaction tubes and is allowed to hybridize with the single-stranded B sequences incorporated into amplification products, which, as described, serve as the first detection oligonucleotide probes, if any are  
30 present.

Following detection of the proximity labeling signal, the reaction tube is brought to 37°C, and 0.4 units of Exonuclease VII in a buffer which consists of 70 mM Tris.Cl, pH 8.0; 8 mM EDTA; 10 mM  $\beta$ -mercaptoethanol; 50  $\mu$ g/ml  
35 BSA is added to the tube. The reaction mixture is incubated for 30 minutes, to cleave single-stranded D protecting sequences. After the Exonuclease VII treatment, avidin coated magnetic beads are added to the reaction tube which is placed on a shaker for 10 minutes, to allow capturing of the biotinylated double-stranded DNA to the avidin molecules. The reaction tube is rotated at 180° to

allow the magnetic beads to adhere to the cap, after which the reaction tube is re-rotated at 180°, and the Isoluminol released to the solution from single-stranded D fragment, via the nuclease activity, is detected by a luminometer (Perkin Elmer).

5

If the first detection method yielded a positive signal, then the examined nucleic acid contains the wild-type sequence whereas if the first detection method did not yield a signal then the examined nucleic acid does not contain the wild-type sequence. If the second detection method yielded a positive signal  
10 than the examined nucleic acid contains the mutant sequence whereas if the second detection method did not yield a signal then the examined nucleic acid does not contain the mutant sequence.

This give rise to three alternative results: (1) if the first detection method  
15 yielded a positive result whereas the second did not, the examined DNA sample is homozygous for the codon 245 (GGC) of the human *p53* gene; (2) if the second detection method yielded a positive result whereas the first did not, the examined DNA sample is homozygous for the codon 245 (GAC) point mutation of the human *p53* gene; (3) if, on the other hand, both, first and second, detection  
20 methods yielded a positive signal, then the examined DNA sample is heterozygous at codon 245 of the human *p53* gene, that is one allele has the wild-type sequence whereas the second allele has the mutant sequence.

#### EXAMPLE 4

25

Diagnostic kits for carrying out a preferred embodiment of the methods according to the present invention detailed above may contain the following constituents:

30 A diagnostic kit for amplifying specific nucleotide sequences in samples, consists of two or more oligonucleotide probes complementary pairs and at least one buffer.

35 One diagnostic kit for detecting the presence of specific nucleotide sequences in samples, consists: (a) two or more oligonucleotide probes complementary pairs; (b) two or more detection oligonucleotide probes conjugated to a proximity labeling moiety; and (c) at least one buffer;

A second diagnostic kit for detecting the presence of specific nucleotide sequences in samples, consists: (a) two or more oligonucleotide probes complementary pairs, one or more are conjugated to a separation moiety, and one or more are conjugated to a label moiety; (b) a single-strand specific nuclease; and (e) a solid support for affinity separation of amplification products.

When the kits are to be used in the screening for the presence of one or all of the various known genetic diseases, e.g., those listed in Table I above, it may contain any suitable number oligonucleotide probes in any suitable combination for screening for mutations in particular disease related genes. In cases where a particular disease related gene may have one or more mutations, e.g., the CFTR gene, the kit should contain the specific oligonucleotide probes for screening the more common of the mutations, which may be different for different intended populations. When the kit is to be used for blood or tissue typing analysis it may contain any combination of oligonucleotide probes, each designed to identify a particular blood or tissue type. Depending on the circumstances, all of the kits may also contain an additional oligonucleotide probes for determining the presence or absence of a nucleic acid sequence corresponding specifically to the presence of a pathogen, for example, the presence of the AIDS virus or a specific strain of such virus, e.g., HIV-I, HIV-II or HIV-III. Accordingly, one kit may be used for testing any number of genes or gene sites within a single gene, and this only requires that the kit contain a number of the specific oligonucleotide probes, all the other components of the kit being the same in all cases.

While the invention has been described with respect to a limited number of embodiments, it will be appreciated that many variations, modifications and other applications of the invention may be made.



SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- 5 (i) APPLICANT: David Segev
- (ii) TITLE OF INVENTION: Non-enzymatic method for  
detecting nucleic acid sequences  
and kits therefore.
- (iii) NUMBER OF SEQUENCES: 16
- (iv) CORRESPONDENCE ADDRESS:
- 10 (A) ADDRESSEE: Mark M. Friedman c/o Robert  
Sheinbein
- (B) STREET: 2940 Birchtree space lane
- (C) CITY: Silver Spring
- (D) STATE: Maryland
- 15 (E) COUNTRY: United States of America
- (F) ZIP: 20906
- (v) COMPUTER READABLE FROM:
- (A) MEDIUM TYPE: 1.44 megabyte, 3.5" microdisk
- (B) COMPUTER: Chicony NB5500/386SX
- 20 (C) OPERATING SYSTEM: MS DOS version 6.2,  
Windows version 3.1
- (D) SOFTWARE: Word for Windows version 2.0  
conv. to ASCII
- (vi) CURRENT APPLICATION DATA:
- 25 (A) APPLICATION NUMBER:
- (B) FILLING DATE:
- (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATE:
- (A) APPLICATION NUMBER:
- 30 (B) FILLING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Friedmam, Mark M.
- (B) REGISTRATION NUMBER: 33,883
- (C) REFERENCE/DOCKET NUMBER: 128/8
- 35 (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: 972-3-6938541
- (B) TELEFAX: 972-3-6938542
- (C) TELEX:

- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 54
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
AGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACC  
TCTGGACAATTACCCGTGTGATCCTTAAACACACGGGGTAGACAAGAGTCTTTGG
- (2) INFORMATION FOR SEQ ID NO:2:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 34
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  
GGGTAGGAUTCCTAGTGTGCCCATTAAACAGGTCT
- (2) INFORMATION FOR SEQ ID NO:3:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 29
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:  
GGTTTCTGAGAACAGATGGGGCACACAAU
- (2) INFORMATION FOR SEQ ID NO:4:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 34
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
AGACCTGTTAATGGGCACACTAGGAAUCCTACCC
- (2) INFORMATION FOR SEQ ID NO:5:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 27
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:  
UGTGTGCCCCATCTGTTCTCAGAAACC

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCA  
ATGTACACATTGTCAAGGACGTACCCGCCGTACTTGGCCTCCGGGTAGGAGTGGTAGT

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCA  
ATGTACACATTGTCAAGGACGTACCCGCTGTACTTGGCCTCCGGGTAGGAGTGGTAGT

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTACTAAGGCCCGCCCATGCAGGAAGTGTACACATGTA

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TGATGGTGAGGATGGGCCTCCGGTTCATG

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TACATGTGTAACAGTTCCTGCATGGGCGGGCCTTAGTAG

## (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29

78

- (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:  
5 CATGAACCGGAGGCCCATCCTCACCATCA
- (2) INFORMATION FOR SEQ ID NO:12:  
(i) SEQUENCE CHARACTERISTICS:  
10 (A) LENGTH: 10  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:  
15 GCCTTAGTAG
- (2) INFORMATION FOR SEQ ID NO:13:  
(i) SEQUENCE CHARACTERISTICS:  
20 (A) LENGTH: 39  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:  
25 GCAATAGCTATCGCCCATGCAGGAACTGTTACACATGTA
- (2) INFORMATION FOR SEQ ID NO:14:  
(i) SEQUENCE CHARACTERISTICS:  
30 (A) LENGTH: 29  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:  
35 TGATGGTGAGGATGGGCCTCCGGTTCATG
- (2) INFORMATION FOR SEQ ID NO:15:  
(i) SEQUENCE CHARACTERISTICS:  
40 (A) LENGTH: 39  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:  
45 TACATGTGTAACAGTTCCTGCATGGGCAGTAGCTATTGC
- (2) INFORMATION FOR SEQ ID NO:16:  
(i) SEQUENCE CHARACTERISTICS:  
50 (A) LENGTH: 29  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:  
CATGAACCGGAGGCCCATCCTCACCATCA

What is claimed is:

1. A process for amplifying and detecting, in a sample containing a nucleic acid of interest, a single stranded target nucleic acid molecule including a target sequence or a double stranded nucleic acid target molecule including a target sequence and target complementary sequence, the process comprising the steps of:
- contacting a first oligonucleotide probe complement pair and a second oligonucleotide probe complement pair with stretches of nucleotide bases present in the nucleic acids of interest, wherein:
- (i) the first oligonucleotide probe complement pair includes oligonucleotide probe 1 and oligonucleotide probe 1' and the second oligonucleotide probe complement pair includes oligonucleotide probe 2 and oligonucleotide probe 2';
  - (ii) said oligonucleotide probe 1 includes a targeting sequence A, which includes a long part  $\alpha$  and a short part  $\alpha'$ , and of a protecting sequence B; said oligonucleotide probe 1' includes a targeting sequence A' and a protecting sequence B';
  - (iii) said oligonucleotide probe 2 includes a targeting sequence C; said oligonucleotide probe 2' includes a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ ;
  - (iv) said part  $\alpha$  of targeting sequence A of oligonucleotide probe 1 and said targeting sequence A' of oligonucleotide probe 1' are complementary to each other;
  - (v) said targeting sequence C of oligonucleotide probe 2 and said part  $\gamma$  of targeting sequence C' of oligonucleotide probe 2' are complementary to each other; said part  $\gamma'$  of targeting sequence C' of oligonucleotide probe 2' and said part  $\alpha'$  of sequence A of oligonucleotide probe 1 are complementary to each other;
  - (vi) said oligonucleotide probes 1 and 2 form a first oligonucleotide pair wherein said targeting sequence A of oligonucleotide probe 1

and said targeting sequence C of oligonucleotide probe 2 are complementary to adjacent portions of the target sequence;

- 5 (vii) said oligonucleotide probes 1' and 2' form a second oligonucleotide pair wherein said targeting sequence A' of oligonucleotide probe 1' and said targeting sequence C' of oligonucleotide probe 2' are complementary to adjacent portions of the target complementary sequence;
- 10 (viii) said protecting sequence B does not hybridize to the target sequence when said targeting sequence A and targeting sequence C hybridize to the target sequence;
- 15 (ix) said protecting sequence B' does not hybridize to the target complementary sequence when said targeting sequence A' and targeting sequence C' hybridize to the target complementary sequence;
- 20 (x) in the junction of said targeting sequence A and said protecting sequence B, a chemical functionality group X1 is attached to a sugar or base moiety of the last nucleotide in said targeting sequence A of oligonucleotide probe 1; a sugar or base moiety of the end-nucleotide of said targeting sequence C of oligonucleotide probe 2 is modified with a chemical functionality group Y1;
- 25 said chemical functionality group X1 is reactive with said chemical functionality group Y1;
- 30 (xi) in the junction of said targeting sequence A' and said protecting sequence B', a chemical functionality group X2 is attached to a sugar or base moiety of the last nucleotide in said sequence A' of oligonucleotide probe 1'; a sugar or base moiety of the end-nucleotide of said targeting sequence C' of oligonucleotide probe 2' is modified with a chemical functionality group Y2; said chemical functionality group X2 is reactive with said chemical functionality group Y2;
- 35 (xii) when said targeting sequence A and said targeting sequence C hybridize to the target sequence, said chemical functionality group X1 reacts with said chemical functionality group Y1 to form a

first chemical bond, and a complementary strand of joined oligonucleotide product is formed; when said targeting sequence A' and said targeting sequence C' hybridize to the target complementary sequence, said chemical functionality group X2 reacts with said chemical functionality group Y2 to form a second chemical bond, and a complementary strand of joined oligonucleotide product is formed;

- (b) providing hybridization conditions to enable said targeting sequence A of oligonucleotide probe 1 and said targeting sequence C of oligonucleotide probe 2 to hybridize with said adjacent portions of the target sequence and to enable said targeting sequence A' of oligonucleotide probe 1' and said targeting sequence C' of oligonucleotide probe 2' to hybridize with said adjacent portions of the target complementary sequence;
- (c) providing conditions which will enable the joining of said oligonucleotide probe 1 and oligonucleotide probe 2, hybridized after step (b) to said adjacent portions of the target sequence, to each other by forming said first chemical bond between said chemical functionality groups X1 and Y1, thereby forming the first joined oligonucleotide product having the target complementary sequence;
- (d) providing conditions which will enable the joining of said oligonucleotide probe 1' and oligonucleotide probe 2', hybridized after step (b) to said adjacent portions of the target complementary sequence, to each other by forming said second chemical bond between said chemical functionality groups X2 and Y2, thereby forming the second joined oligonucleotide product having the target sequence;
- (e) treating the sample under a denaturing condition;
- (f) repeating steps (b) through (e) a desired number of times; and
- (g) detecting the joined oligonucleotide products.

2. A process for linear amplification and detection, in a sample containing a nucleic acid of interest, of a single stranded target nucleic acid molecule including a target sequence or a double stranded nucleic acid target

molecule including a target sequence and target complementary sequence, the process comprising the steps of:

- (a) contacting a first oligonucleotide probe pair or a second oligonucleotide probe pair with stretches of nucleotide bases present in the nucleic acids of interest, wherein:
- (i) the first oligonucleotide probe pair includes oligonucleotide probe 1 and oligonucleotide probe 2 and the second oligonucleotide probe pair includes oligonucleotide probe 1' and oligonucleotide probe 2';
  - (ii) said oligonucleotide probe 1 includes a targeting sequence A and a protecting sequence B; said oligonucleotide probe 1' includes a targeting sequence A' and a protecting sequence B';
  - (iii) said oligonucleotide probe 2 includes a targeting sequence C; said oligonucleotide probe 2' includes a targeting sequence C';
  - (iv) said targeting sequence A of oligonucleotide probe 1 and said targeting sequence C of oligonucleotide probe 2 are complementary to adjacent portions of the target sequence;
  - (v) said targeting sequence A' of oligonucleotide probe 1' and said targeting sequence C' of oligonucleotide probe 2' are complementary to adjacent portions of the target complementary sequence;
  - (vi) said protecting sequence B does not hybridize to the target sequence when said targeting sequence A and targeting sequence C hybridize to the target sequence;
  - (vii) said protecting sequence B' does not hybridize to the target complementary sequence when said targeting sequence A' and said targeting sequence C' hybridize to the target complementary sequence;
  - (viii) in the junction of said targeting sequence A and said protecting sequence B, a chemical functionality group X1 is attached to a



5 sugar or base moiety of the last nucleotide in said sequence A of oligonucleotide probe 1; a sugar or base moiety of the end-nucleotide of said targeting sequence C of oligonucleotide probe 2 is modified with a chemical functionality group Y1; said chemical functionality group X1 is reactive with said chemical functionality group Y1;

10 (ix) in the junction of said targeting sequence A' and said protecting sequence B', a chemical functionality group X2 is attached to a sugar or base moiety of the last nucleotide in said sequence A' of oligonucleotide probe 1'; a sugar or base moiety of the end-nucleotide of said targeting sequence C' of oligonucleotide probe 2' is modified with a chemical functionality group Y2; said chemical functionality group X2 is reactive with said chemical functionality group Y2;

20 (x) when said targeting sequence A and targeting sequence C hybridize to the target sequence, said chemical functionality group X1 reacts with said chemical functionality group Y1 to form a chemical bond, and a complementary strand of joined oligonucleotide product is formed; when said targeting sequence A' and targeting sequence C' hybridize to the target complementary sequence, said chemical functionality group X2 reacts with said chemical functionality group Y2 to form an alternative chemical bond, a complementary strand of joined oligonucleotide product is formed;

30 (b) providing hybridization conditions to enable targeting sequence A of oligonucleotide probe 1 and targeting sequence C of oligonucleotide probe 2 to hybridize with adjacent portions of the target sequence or to enable targeting sequence A' of oligonucleotide probe 1' and targeting sequence C' of oligonucleotide probe 2' to hybridize with adjacent portions of the target complementary sequence;

35 (c) providing conditions which will enable the joining of said oligonucleotide probe 1 and oligonucleotide probe 2, hybridized after step (b) to said adjacent portions of the target sequence, to each other by forming said chemical bond between chemical functionality groups X1 and Y1, thereby forming said joined oligonucleotide product having the target complementary sequence; or providing conditions which will enable the

5 joining of said oligonucleotide probe 1' and oligonucleotide probe 2',  
hybridized after step (b) to said adjacent portions of the target  
complementary sequence, to each other by forming said alternative  
chemical bond between said chemical functionality groups X2 and Y2,  
thereby forming said joined oligonucleotide product having the target  
sequence;

- (d) treating the sample under a denaturing condition;
- 10 (f) repeating steps (b) through (d) a desired number of times; and
- (g) detecting the joined oligonucleotide product.

3. A process for amplifying and detecting, in a sample containing a  
15 nucleic acid of interest, a single stranded target nucleic acid molecule including a  
wild type target sequence and/or a single stranded target nucleic acid molecule  
including a mutant target sequence, or a double stranded nucleic acid target  
molecule including a wild-type target sequence and wild-type target  
complementary sequence, and/or a double stranded nucleic acid target molecule  
20 including mutant target sequence and mutant target complementary sequence, the  
process comprising the steps of:

- (a) contacting a first and a second oligonucleotide probes set with stretches of  
nucleotide bases present in the nucleic acids of interest, wherein:
  - 25 (i) the first oligonucleotide probes set is designed to amplify the wild-  
type sequences and includes four oligonucleotide probes  
designated 1, 1', 2 and 2'; said oligonucleotide probes 1 and 1'  
form a first oligonucleotide probe complementary pair; said  
30 oligonucleotide probes 2 and 2' form a second oligonucleotide  
probe complementary pair; said oligonucleotide probes 1 and 2  
form a first oligonucleotide probe pair; said oligonucleotide  
probes 1' and 2' form a second oligonucleotide probe pair;
  - 35 (ii) the second oligonucleotide probes set is designed to amplify the  
mutant sequences and includes four oligonucleotide probes  
designated 3, 3', 4 and 4'; said oligonucleotide probes 3 and 3'  
form a third oligonucleotide probe complementary pair; said  
oligonucleotide probes 4 and 4' form a fourth oligonucleotide

probe complementary pair; said oligonucleotide probes 3 and 4 form a third oligonucleotide probe pair; said oligonucleotide probes 3' and 4' form a fourth oligonucleotide probe pair;

- 5 (iii) said oligonucleotide probes 1 and 3 each includes a targeting sequence A, which includes a long part  $\alpha$  and a short part  $\alpha'$ , and a protecting sequence B and D, respectively; said oligonucleotide probes 1' and 3' each includes a targeting sequence A' and a protecting sequence B' and D',  
10 respectively;
- (iv) said oligonucleotide probes 2 and 4 each includes of a targeting sequence C; said oligonucleotide probes 2' and 4' each includes a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ ;  
15
- (v) said part  $\alpha$  of targeting sequences A of oligonucleotide probes 1 and 3 and said targeting sequences A' of oligonucleotide probes 1' and 3' are complementary to each other, respectively;  
20
- (vi) said targeting sequences C of oligonucleotide probes 2 and 4 and said part  $\gamma$  of targeting sequences C' of oligonucleotide probes 2' and 4' are complementary to each other, respectively; said part  $\gamma'$  of targeting sequences C' of oligonucleotide probes 2' and 4' and said  
25 part  $\alpha'$  of targeting sequences A of oligonucleotide probes 1 and 3 are complementary to each other, respectively;
- (vii) the sequence of said oligonucleotide probes 3' and 4 of the second oligonucleotide probes set is identical or closely similar to the  
30 sequence of said oligonucleotide probes 1' and 2 of the first oligonucleotide probes set, respectively; the sequence of said oligonucleotide probes 3 and 4' of the second oligonucleotide probes set differ from that of said oligonucleotide probes 1' and 2 of the first oligonucleotide probes set, respectively, in a position of  
35 a sequence alteration to be determined, so that said oligonucleotide probes 1 and 2' are fully complementary to the wild-type target sequence and the wild-type target complementary sequence, respectively, at that position, and said oligonucleotide probes 3 and 4' are fully complementary to the mutant target sequence and the

mutant target complementary sequence, respectively, at that position;

- 5 (viii) said targeting sequence A of oligonucleotide probe 1 and said targeting sequence C of oligonucleotide probe 2 are complementary to adjacent portions of the wild-type target sequence; said targeting sequence A of oligonucleotide probe 3 and said targeting sequence C of oligonucleotide probe 4 are complementary to adjacent portions of the mutant target sequence;
- 10 (ix) said targeting sequence A' of oligonucleotide probe 1' and said targeting sequence C' of oligonucleotide probe 2' are complementary to adjacent portions of the wild-type target complementary sequence; said targeting sequence A' of
- 15 oligonucleotide probe 3' and said targeting sequence C' of oligonucleotide probe 4' are complementary to adjacent portions of the mutant target complementary sequence;
- 20 (x) said protecting sequences B and D do not hybridize to the wild-type or the mutant target sequences, respectively, when said targeting sequences A and targeting sequences C hybridize to these target sequences;
- 25 (xi) said protecting sequences B' and D' do not hybridize to the wild-type or the mutant target complementary sequences, respectively, when said targeting sequences A' and targeting sequences C' hybridize to these target complementary sequence;
- 30 (xii) in the junction of said targeting sequence A and said protecting sequence B of oligonucleotide probe 1, a chemical functionality group X1 is attached to a sugar or base moiety of the last nucleotide of said targeting sequence A; a sugar or base moiety of the end-nucleotide of said targeting sequence C of
- 35 oligonucleotide probe 2 is modified with a chemical functionality group Y1; said chemical functionality group X1 is reactive with said chemical functionality group Y1;
- (xiii) in the junction of said targeting sequence A and said protecting sequence D of oligonucleotide probe 3, a chemical functionality

group X3 is attached to a sugar or base moiety of the last nucleotide of said targeting sequence A; a sugar or base moiety of the end-nucleotide of said targeting sequence C of oligonucleotide probe 4 is modified with a chemical functionality group Y3; said chemical functionality group X3 is reactive with said chemical functionality group Y3;

5

(xiv) in the junction of said targeting sequence A' and said protecting sequence B' of oligonucleotide probe 1', a chemical functionality group X2 is attached to a sugar or base moiety of the last nucleotide of said targeting sequence A'; the sugar or base moiety of the end-nucleotide of said targeting sequence C' of oligonucleotide probe 2' is modified with a chemical functionality group Y2; said chemical functionality group X2 is reactive with said chemical functionality group Y2;

10

15

(xv) in the junction of said targeting sequence A' and said protecting sequence D' of oligonucleotide probe 3', a chemical functionality group X4 is attached to a sugar or base moiety of the last nucleotide of said targeting sequence A'; a sugar or base moiety of the end-nucleotide of said targeting sequence C' of oligonucleotide probe 4' is modified with a chemical functionality group Y4; said chemical functionality group X4 is reactive with said chemical functionality group Y4;

20

25

(xvi) when said targeting sequence A and said targeting sequence C of oligonucleotide probes 1 and 2, respectively, hybridize to the wild-type target sequence, said chemical functionality group X1 reacts with said chemical functionality group Y1 to form a first chemical bond, and a complementary strand of wild-type joined oligonucleotide product is formed; when said targeting sequence A' and said targeting sequence C' of oligonucleotide probes 1' and 2' hybridize to the wild-type target complementary sequence, said chemical functionality group X2 reacts with chemical functionality group Y2 to form a second chemical bond, and a strand of wild-type joined oligonucleotide product is formed;

30

35

(xvii) when said targeting sequence A and said targeting sequence C of oligonucleotide probes 3 and 4, respectively, hybridize to the

mutant target sequence, said chemical functionality group X3 reacts with said chemical functionality group Y3 to form a third chemical bond, and a complementary strand of mutant joined oligonucleotide product is formed; when said targeting sequence A' and said targeting sequence C' of oligonucleotide probes 3' and 4', respectively, hybridize to the mutant target complementary sequence, said chemical functionality group X4 reacts with said chemical functionality group Y4 to form a fourth chemical bond, and a strand of mutant joined oligonucleotide product is formed;

- (b) providing hybridization conditions to enable:
- (i) said targeting sequence A of oligonucleotide probe 1 and said targeting sequence C of oligonucleotide probe 2 to hybridize with said adjacent portions of the wild-type target sequence;
  - (ii) said targeting sequence A' of oligonucleotide probe 1' and said targeting sequence C' of oligonucleotide probe 2' to hybridize with said adjacent portions of the wild-type target complementary sequence;
  - (iii) said targeting sequence A of oligonucleotide probe 3 and said targeting sequence C of oligonucleotide probe 4 to hybridize with said adjacent portions of the mutant target sequence;
  - (iv) said targeting sequence A' of oligonucleotide probe 3' and said targeting sequence C' of oligonucleotide probe 4' to hybridize with said adjacent portions of the mutant target complementary sequence;
- (c) providing conditions which will enable the joining of said oligonucleotide probe 1 and said oligonucleotide probe 2, hybridized after step (b) to said adjacent portions of the wild-type target sequence, to each other, by forming said first chemical bond between said chemical functionality groups X1 and Y1, thereby forming said joined oligonucleotide product having the wild-type target complementary sequence;

- 5 (d) providing conditions which will enable the joining of said oligonucleotide probe 1' and said oligonucleotide probe 2', hybridized after step (b) to said adjacent portions of the wild-type target complementary sequence, to each other by forming said second chemical bond between said chemical functionality groups X2 and Y2, thereby forming said joined oligonucleotide product having the wild-type target sequence;
- 10 (e) providing conditions which will enable the joining of said oligonucleotide probe 3 and said oligonucleotide probe 4, hybridized after step (b) to said adjacent portions of the mutant target sequence, to each other by forming said third chemical bond between said chemical functionality groups X3 and Y3, thereby forming said joined oligonucleotide product having the mutant target complementary sequence;
- 15 (f) providing conditions which will enable the joining of said oligonucleotide probe 3' and said oligonucleotide probe 4', hybridized after step (b) to said adjacent portions of the mutant target complementary sequence, to each other, by forming said fourth chemical bond between said chemical functionality groups X4 and Y4, thereby forming said joined oligonucleotide product having the mutant target sequence;
- 20 (g) treating the sample under a denaturing condition;
- (h) repeating steps (b) through (g) a desired number of times; and
- 25 (i) detecting the joined oligonucleotide products.

4. A process as of claims 1, 2 or 3 wherein said oligonucleotide probes 1, 1', 2, 2' are selected from twelve alternative groups of which in the first said oligonucleotide probe 1 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ , and a protecting sequence B; said oligonucleotide probe 1' has a targeting sequence A' which is shorter than said targeting sequence A of said oligonucleotide probe 1; said oligonucleotide probe 2 has a targeting sequence C; said oligonucleotide probe 2' has a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ , and is longer than said targeting sequence C of said oligonucleotide probe 2 and a protecting sequence B'; in the second, said oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; said oligonucleotide probe 1' has a targeting sequence A' which includes a long part  $\alpha$  and a short part  $\alpha'$ , and is longer than said targeting

30

35

sequence A of said oligonucleotide probe 1; said oligonucleotide probe 2 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ ; said oligonucleotide probe 2' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 2 and a protecting sequence B'; in the third, said oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; said oligonucleotide probe 1' has a targeting sequence A' which equals in length to said targeting sequence A of said oligonucleotide probe 1; said oligonucleotide probe 2 has a targeting sequence C; said oligonucleotide probe 2' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 2 and a protecting sequence B'; in the fourth, said oligonucleotide probe 1 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ , and a protecting sequence B; said oligonucleotide probe 1' has a targeting sequence A' which is shorter than said targeting sequence A of said oligonucleotide probe 1 and a protecting sequence B'; said oligonucleotide probe 2 has a targeting sequence C; said oligonucleotide probe 2' has a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ , and is longer than said targeting sequence C of said oligonucleotide probe 2; in the fifth said oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; said oligonucleotide probe 1' has a targeting sequence A' which includes a long part  $\alpha$  and a short part  $\alpha'$ , and is longer than said targeting sequence A of said oligonucleotide probe 1 and a protecting sequence B'; said oligonucleotide probe 2 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ ; said oligonucleotide probe 2' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 2; in the sixth, said oligonucleotide probe 1 has a targeting sequence A and a protecting sequence B; said oligonucleotide probe 1' has a targeting sequence A' which equals in length to said targeting sequence A of said oligonucleotide probe 1 and a protecting sequence B'; said oligonucleotide probe 2 has a targeting sequence C; said oligonucleotide probe 2' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 2; in the seventh, said oligonucleotide probe 1 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ ; said oligonucleotide probe 1' has a targeting sequence A' which is shorter than said sequence A of said oligonucleotide probe 1; said oligonucleotide probe 2 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ , and a protecting sequence B; said oligonucleotide probe 2' has a targeting sequence C' which is longer than said targeting sequence C of said oligonucleotide probe 2 and a protecting sequence B'; in the eighth, said oligonucleotide probe 1 has a targeting sequence A; said oligonucleotide probe 1' has a targeting sequence A' which includes a long part  $\alpha$



and a short part  $\alpha'$ , and is longer than said sequence A of said oligonucleotide probe 1; said oligonucleotide probe 2 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ , and a protecting sequence B; said oligonucleotide probe 2' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 2 and a protecting sequence B'; in the ninth, said oligonucleotide probe 1 has a targeting sequence A; said oligonucleotide probe 1' has a targeting sequence A' which equals in length to said sequence A of said oligonucleotide probe 1; said oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B; said oligonucleotide probe 2' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 2 and a protecting sequence B'; in the tenth, said oligonucleotide probe 1 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ ; said oligonucleotide probe 1' has a targeting sequence A' which is shorter than said targeting sequence A of said oligonucleotide probe 1 and a protecting sequence B; said oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B'; said oligonucleotide probe 2' has a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ , and is longer than said targeting sequence C of said oligonucleotide probe 2; in the eleventh, said oligonucleotide probe 1 has a targeting sequence A; said oligonucleotide probe 1' has a targeting sequence A' which includes a long part  $\alpha$  and a short part  $\alpha'$ , and is longer than said targeting sequence A of said oligonucleotide probe 1 and a protecting sequence B; said oligonucleotide probe 2 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ , and a protecting sequence B'; said oligonucleotide probe 2' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 2; and in the twelfth, said oligonucleotide probe 1 has a targeting sequence A; said oligonucleotide probe 1' has a targeting sequence A' which equals in length to said targeting sequence A of said oligonucleotide probe 1 and a protecting sequence B; said oligonucleotide probe 2 has a targeting sequence C and a protecting sequence B'; said oligonucleotide probe 2' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 2.

5. A process as of claims 4 wherein said oligonucleotide probes 3, 3', 4, 4' are selected from twelve alternative groups of which in the first group said oligonucleotide probe 3 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ , and a protecting sequence D; said oligonucleotide probe 3' has a targeting sequence A' which is shorter than said targeting sequence A of said oligonucleotide probe 3; said oligonucleotide probe 4 has a targeting

sequence C; said oligonucleotide probe 4' has a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ , and is longer than said targeting sequence C of said oligonucleotide probe 4 and a protecting sequence D'; in the second, said oligonucleotide probe 3 has a targeting sequence A and a protecting sequence D; said oligonucleotide probe 3' has a targeting sequence A' which includes a long part  $\alpha$  and a short part  $\alpha'$ , and is longer than said targeting sequence A of said oligonucleotide probe 3; said oligonucleotide probe 4 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ ; said oligonucleotide probe 4' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 4 and a protecting sequence D'; in the third, said oligonucleotide probe 3 has a targeting sequence A and a protecting sequence D; said oligonucleotide probe 3' has a targeting sequence A' which equals in length to said targeting sequence A of said oligonucleotide probe 3; said oligonucleotide probe 4 has a targeting sequence C; said oligonucleotide probe 4' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 4 and a protecting sequence D'; in the fourth, said oligonucleotide probe 3 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ , and a protecting sequence D; said oligonucleotide probe 3' has a targeting sequence A' which is shorter than said targeting sequence A of said oligonucleotide probe 3 and a protecting sequence D'; said oligonucleotide probe 4 has a targeting sequence C; said oligonucleotide probe 4' has a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ , and is longer than said targeting sequence C of said oligonucleotide probe 4; in the fifth, said oligonucleotide probe 3 has a targeting sequence A and a protecting sequence D; said oligonucleotide probe 3' has a targeting sequence A' which includes a long part  $\alpha$  and a short part  $\alpha'$ , and is longer than said targeting sequence A of said oligonucleotide probe 3 and a protecting sequence D'; said oligonucleotide probe 4 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ ; said oligonucleotide probe 4' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 4; in the sixth, said oligonucleotide probe 3 has a targeting sequence A and a protecting sequence D; said oligonucleotide probe 3' has a targeting sequence A' which equals in length to said targeting sequence A of said oligonucleotide probe 3 and a protecting sequence D'; said oligonucleotide probe 4 has a targeting sequence C; said oligonucleotide probe 4' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 4; in the seventh, said oligonucleotide probe 3 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ ; said oligonucleotide probe 3' has a targeting sequence A' which is shorter than said sequence A of said

oligonucleotide probe 3; said oligonucleotide probe 4 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ , and a protecting sequence D; said oligonucleotide probe 4' has a targeting sequence C' which is longer than said targeting sequence C of said oligonucleotide probe 4 and a protecting sequence D'; in the eighth, said oligonucleotide probe 3 has a targeting sequence A; said oligonucleotide probe 3' has a targeting sequence A' which includes a long part  $\alpha$  and a short part  $\alpha'$ , and is longer than said sequence A of said oligonucleotide probe 3; said oligonucleotide probe 4 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ , and a protecting sequence D; said oligonucleotide probe 4' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 4 and a protecting sequence D'; in the ninth, said oligonucleotide probe 3 has a targeting sequence A; said oligonucleotide probe 3' has a targeting sequence A' which equals in length to said sequence A of said oligonucleotide probe 3; said oligonucleotide probe 4 has a targeting sequence C and a protecting sequence D; said oligonucleotide probe 4' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 4 and a protecting sequence D'; in the tenth, said oligonucleotide probe 3 has a targeting sequence A which includes a long part  $\alpha$  and a short part  $\alpha'$ ; said oligonucleotide probe 3' has a targeting sequence A' which is shorter than said targeting sequence A of said oligonucleotide probe 3 and a protecting sequence D; said oligonucleotide probe 4 has a targeting sequence C and a protecting sequence D'; said oligonucleotide probe 4' has a targeting sequence C' which includes a long part  $\gamma$  and a short part  $\gamma'$ , and is longer than said targeting sequence C of said oligonucleotide probe 4; in the eleventh, said oligonucleotide probe 3 has a targeting sequence A; said oligonucleotide probe 3' has a targeting sequence A' which includes a long part  $\alpha$  and a short part  $\alpha'$ , and is longer than said targeting sequence A of said oligonucleotide probe 3 and a protecting sequence D; said oligonucleotide probe 4 has a targeting sequence C which includes a long part  $\gamma$  and a short part  $\gamma'$ , and a protecting sequence D'; said oligonucleotide probe 4' has a targeting sequence C' which is shorter than said targeting sequence C of said oligonucleotide probe 4; and in the twelfth, said oligonucleotide probe 3 has a targeting sequence A; said oligonucleotide probe 3' has a targeting sequence A' which equals in length to said targeting sequence A of said oligonucleotide probe 3 and a protecting sequence D; said oligonucleotide probe 4 has a targeting sequence C and a protecting sequence D'; said oligonucleotide probe 4' has a targeting sequence C' which equals in length to said targeting sequence C of said oligonucleotide probe 4.

6. A process as of claims 1, 2, 3, 4 or 5 wherein the number of nucleotides contained in the  $\alpha'$  and  $\gamma'$  parts equals 5 or 4 or 3 or 2 or 1 or zero nucleotides.

5 7. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1 is an electrophile and said chemical functionality group Y1 is a nucleophile.

10 8. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1 is a nucleophile and said chemical functionality group Y1 is an electrophile.

15 9. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X2 is an electrophile and said chemical functionality group Y2 is a nucleophile.

20 10. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X2 is a nucleophile and said chemical functionality group Y2 is an electrophile.

11. A process as of claims 3, 5 or 6 wherein said chemical functionality group X3 is an electrophile and said chemical functionality group Y3 is a nucleophile.

25 12. A process as of claims 3, 5 or 6 wherein said chemical functionality group X3 is a nucleophile and said chemical functionality group Y3 is an electrophile.

30 13. A process as of claims 3, 5 or 6 wherein said chemical functionality group X4 is an electrophile and said chemical functionality group Y4 is a nucleophile.

35 14. A process as of claims 3, 5 or 6 wherein said chemical functionality group X4 is a nucleophile and said chemical functionality group Y4 is an electrophile.

15. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1, X2, Y1 or Y2 replaces a hydroxyl group located at a C-2' position of a ribose ring of a nucleotide in said oligonucleotide probes 1, 1', 2

or 2', respectively.

16. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1, X2, Y1 or Y2 replaces a hydrogen in a hydroxyl group located at a C-2' position of a ribose ring of a nucleotide in said oligonucleotide probes 1, 1', 2 or 2', respectively.

17. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1, X2, Y1 or Y2 replaces a hydrogen in an amino group located at a C-6 position of an adenine or cytidine residue in said oligonucleotide probes 1, 1', 2 or 2', respectively.

18. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1, X2, Y1 or Y2 replaces a hydrogen located at a C-8 position of an adenine or guanine residue in said oligonucleotide probes 1, 2, 1' or 2', respectively.

19. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1, X2, Y1 or Y2 replaces a hydrogen from a methyl group located at a C-5 position of a thymidine residue in said oligonucleotide probes 1, 1', 2 or 2', respectively.

20. A process as of claims 3, 5 or 6 wherein said chemical functionality group X3, X4, Y3 or Y4 replaces a hydroxyl group located at a C-2' position of a ribose ring of a nucleotide in said oligonucleotide probes 3, 3', 4 or 4', respectively.

21. A process as of claims 3, 5 or 6 wherein said chemical functionality group X3, X4, Y3 or Y4 replaces a hydrogen in a hydroxyl group located at a C-2' position of a ribose ring of a nucleotide in said oligonucleotide probes 3, 3', 4 or 4', respectively.

22. A process as of claims 3, 5 or 6 wherein said chemical functionality group X3, X4, Y3 or Y4 replaces a hydrogen in an amino group located at a C-6 position of an adenine or cytidine residue in said oligonucleotide probes 3, 3', 4 or 4', respectively.

23. A process as of claims 3, 5 or 6 wherein said chemical functionality group X3, X4, Y3 or Y4 replaces a hydrogen located at a C-8

position of an adenine or guanine residue in said oligonucleotide probes 3, 3', 4 or 4', respectively.

24. A process as of claims 3, 5 or 6 wherein said chemical  
5 functionality group X3, X4, Y3 or Y4 replaces a hydrogen from a methyl group located at a C-5 position of a thymidine residue in oligonucleotide probes 3, 3', 4 or 4', respectively.

25. A process as of claims 1, 2, 3, 4, 5 or 6 wherein the sequences of  
10 said protecting sequences B and B' are complementary to sequences in an oligonucleotide probe of which said sequences B and B' are part of, in a palindrome manner and therefore protect said chemical functionality groups X1 and X2 from interacting with said chemical functionality groups Y1 and Y2.

15 26. A process as of claims 1, 2, 3, 4, 5 or 6 wherein said chemical functionality group X1, X2, Y1 or Y2 in said oligonucleotide probes 1, 2, 1' or 2', respectively, are protected by oligonucleotides 1.1, 2.1, 1.1' or 2.1', respectively.

20 27. A process as of claims 3, 5 or 6 wherein the nucleic acid sequence of said protecting sequences D and D' are complementary to sequences in an oligonucleotide probe of which said sequences D and D' are part of, in a palindrome manner and therefore protect said chemical functionality groups X3 and X4 from interacting with said chemical functionality groups Y3 and Y4.

25 28. A process as of claims 3, 5 or 6 wherein said chemical functionality group X3, X4, Y3 or Y4 in oligonucleotide probes 3, 4, 3' or 4', respectively, is protected by oligonucleotide 3.1, 4.1, 3.1' or 4.1', respectively.

30 29. A process as of claims 1, 2, 3, 4, 5 or 6 wherein the reaction between said chemical functionality groups X1 and Y1 or X2 and Y2 is a substitution of a nucleophile for an electrophilic leaving group.

35 30. A process as of claims 1, 2, 3, 4, 5 or 6 wherein the reaction between said chemical functionality groups X1 and Y1 or X2 and Y2 is a Michael addition reaction.

31. A process as of claims 1, 2, 3, 4, 5 or 6 wherein the reaction between said chemical functionality groups X1 and Y1 or X2 and Y2 is a Diels-Alder reaction.

5 32. A process as of claims 1, 2, 3, 4, 5 or 6 wherein the reaction between said chemical functionality groups X1 and Y1 or X2 and Y2 is an addition of a thiol group to the double bond of a maleimido moiety.

10 33. A process as of claims 1, 2, 3, 4, 5 or 6 wherein the reaction between said chemical functionality groups X1 and Y1 or X2 and Y2 is a photochemical reaction.

15 34. A process as of claims 1, 2, 3, 4, 5 or 6 wherein the reaction between said chemical functionality groups X1 and Y1 or X2 and Y2 is a [2+2] photocyclodimerization reaction.

20 35. A process as of claims 3, 5 or 6 wherein the reaction between said chemical functionality groups X3 and Y3 or X4 and Y4 is a substitution of a nucleophile for an electrophilic leaving group.

36. A process as of claims 3, 5 or 6 wherein the reaction between chemical said functionality groups X3 and Y3 or X4 and Y4 is a Michael addition reaction.

25 37. A process as of claims 3, 5 or 6 wherein the reaction between said chemical functionality groups X3 and Y3 or X4 and Y4 is a Diels-Alder reaction.

30 38. A process as of claims 3, 5 or 6 wherein the reaction between said chemical functionality groups X3 and Y3 or X4 and Y4 is an addition of a thiol group to the double bond of a maleimido moiety.

35 39. A process as of claims 3, 5 or 6 wherein the reaction between said chemical functionality groups X3 and Y3 or X4 and Y4 is a photochemical reaction.

40. A process as of claims 3, 5 or 6 wherein the reaction between said chemical functionality groups X3 and Y3 or X4 and Y4 is a [2+2] photocyclodimerization reaction.

41. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the oligonucleotide pairs are present as a molar excess in the range of  $10^5$  to  $10^{15}$  pairs per nucleic acid target sequence or target complementary sequence.
- 5 42. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the oligonucleotide probes are substantially complementary to said sequences.
- 10 43. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the oligonucleotide probes are fully complementary to said sequences.
- 15 44. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the target sequence is selected from the group consisting of deoxyribonucleic acid, ribonucleic acid, and a copolymer of deoxyribonucleic acid and ribonucleic acid.
- 20 45. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the oligonucleotide probes include nucleotides selected from the group consisting of oligodeoxyribonucleotides, oligoribonucleotides, protein nucleic acids and their analogs and copolymers of deoxyribonucleotides ribonucleotides and protein nucleic acids and their analogs.
- 25 46. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the target sequence has been synthesized by a polymerase chain reaction.
- 30 47. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the target sequence has been synthesized by a ligase chain reaction.
48. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the target sequence has been synthesized by a chemical amplification reaction.
- 35 49. A process as of claims 1, 2, 3, 4, 5 or 6, wherein said denaturation is accomplished by selecting a method from a group of methods consisting of heating, alkali treatment and enzymatic treatment.
50. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the detection of said joined oligonucleotide products is accomplished by labeling one or more of said oligonucleotide probes in a label selected from a group of labels which consists of radioactive labels, enzymes, chromophores, flourophores,



luminophores, atoms and molecules detectable by electron microscopy and metal ions detectable by their magnetic properties.

51. A process as in claim 50 wherein the detection of said joined  
5 oligonucleotide products is accomplished with a capture assay.

52. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the detection of  
said joined oligonucleotide products is accomplished by size separation.

10 53. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the detection of  
joined oligonucleotide products is accomplished by selecting said chemical  
functionality groups which form a detectable compound when a chemical bond is  
formed between them.

15 54. A process as in claim 53, wherein the detectable compound is  
detected via a detection method selected from a group of methods consisting  
colorimetric, fluorimetric and luminometric methods.

20 55. A process as in claim 53, wherein the detectable compound is  
detected via an antibody.

25 56. A process as of claims 1, 2, 3, 4, 5 or 6, wherein the detection of  
joined oligonucleotide products is based on the presence of single stranded said  
protecting sequences B and B' which are conjugated to said joined  
oligonucleotide products.

30 57. A process as of claims 3, 5 or 6, wherein the detection of said  
joined oligonucleotide products is based on the presence of single stranded said  
protecting sequences D and D' which are conjugated to said joined  
oligonucleotide products.

35 58. A process as of claims 56 or 57, wherein one or more of said single  
stranded protecting sequences B, B', D and D' serves as one or more first  
detection oligonucleotide probe, to which attached is a first proximity energy  
transfer label, and to one or more second detection oligonucleotide probes B.1,  
B'.1, D.1 and D'.1, which are complementary to said protecting sequences B, B',  
D and D', respectively, attached is a second proximity energy transfer label in an  
arrangement that enables energy transfer when said first detection

oligonucleotide probe is hybridized to said second detection oligonucleotide probe.

59. A process as of claims 56 or 57, wherein to one or more locations  
5 of one or more of said single stranded protecting sequences B, B', D and D'  
attached is a label moiety that is released from said joined oligonucleotide  
products by the activity of a single stranded specific nuclease, and to one or  
more locations of one or more of said oligonucleotide probes attached is a  
separation moiety which can bind to a counterpart separation moiety attached to  
10 a solid support.

60. A process as in claim 59, wherein said single stranded specific  
nuclease is selected from a group of single stranded specific nucleases consisting  
Exonuclease 7 from *E. Coli.*, S1 nuclease from *Aspergillus oryzae* and Mung  
15 been nuclease from *Phaseolus aureus*.

61. A process as in claim 59, wherein said label moiety is released  
from said joined oligonucleotide products by a chemical process which  
specifically degrades single-stranded sequences.  
20

62. A diagnostic kit for amplifying and detecting, in a sample  
containing a nucleic acid of interest, a single stranded target nucleic acid  
molecule including a target sequence or a double stranded nucleic acid target  
molecule including a target sequence and a target complementary sequence, the  
25 kit comprising of two or more oligonucleotide probe complementary pairs and at  
least one buffer.

63. A diagnostic kit for linear amplification and detection, in a sample  
containing a nucleic acid of interest, of a single stranded target nucleic acid  
30 molecule including a target sequence or a double stranded nucleic acid target  
molecule including a target sequence and target complementary sequence, the kit  
comprising of one or more oligonucleotide probe pairs and at least one buffer.

64. A diagnostic kit as of claims 62 or 63 further comprising of two or  
35 more detection oligonucleotide probes conjugated to a proximity labeling moiety.

65. A diagnostic kit for amplifying and detecting, in a sample  
containing a nucleic acid of interest, a single stranded target nucleic acid  
molecule including a target sequence or a double stranded nucleic acid target

molecule including a target sequence and target complementary sequence, the kit comprising of two or more oligonucleotide probe complementary pair, one oligonucleotide probe or more is conjugated to a first separation moiety, and one oligonucleotide probe or more is conjugated to a label moiety; a single-strand specific nuclease; and a solid support to which attached is a second corresponding affinity separation moiety.

66. A diagnostic kit for linear amplification and detection, in a sample containing a nucleic acid of interest, of a single stranded target nucleic acid molecule including a target sequence or a double stranded nucleic acid target molecule including a target sequence and target complementary sequence, the kit comprising of one or more oligonucleotide probe pairs, one oligonucleotide probe or more is conjugated to a first separation moiety, and one oligonucleotide probe or more is conjugated to a label moiety; a single-strand specific nuclease; and a solid support to which attached is a second corresponding affinity separation moiety.

67. A diagnostic kit for amplifying and detecting, in a sample containing a nucleic acid of interest, a single stranded target nucleic acid molecule including a wild type target sequence and/or a single stranded target nucleic acid molecule including a mutant target sequence or a double stranded nucleic acid target molecule including a wild-type target sequence and wild-type target complementary sequence, and/or a double stranded nucleic acid target molecule including mutant target sequence and mutant target complementary sequence, the kit comprising the of two or more oligonucleotide probe complementary pairs, one oligonucleotide probe or more is conjugated to a first separation moiety, and one oligonucleotide probe or more is conjugated to a label moiety; a single-strand specific nuclease; and a solid support to which attached is a second corresponding affinity separation moiety, and two or more detection oligonucleotide probes conjugated to a proximity labeling moiety.

68. A process for amplifying and detecting, in a sample containing a nucleic acid of interest, a single stranded target nucleic acid molecule including a wild type target sequence and/or a single stranded target nucleic acid molecule including a mutant target sequence or a double stranded nucleic acid target molecule including a wild-type target sequence and wild-type target complementary sequence, and/or a double stranded nucleic acid target molecule including mutant target sequence and mutant target complementary sequence, the process comprising the steps of the process of claim 5 performed in one or more

vessel wherein a reagent which includes two or more oligonucleotide probe complementary pair, one oligonucleotide probe or more is conjugated to a first separation moiety, and one oligonucleotide probe or more is conjugated to a label moiety; a single-strand specific nuclease; and a solid support to which  
5 attached is a second corresponding affinity separation moiety; and two or more detection oligonucleotide probes conjugated to a proximity labeling moiety, is used.

69. A process of determining the genotype of an individual comprising  
10 the steps of the process of claim 5 performed in one or more vessel wherein a reagent which includes two or more said oligonucleotide probe complementary pairs, one said oligonucleotide probe or more is conjugated to a first separation moiety, and one said oligonucleotide probe or more is conjugated to a label moiety; a single-strand specific nuclease; and a solid support to which attached is  
15 a second corresponding affinity separation moiety; and two or more detection oligonucleotide probes conjugated to a proximity labeling moiety, is used.

70. A process of determining the identity a nucleotide base in a specific position in an allele comprising the steps of the process of claim 5.  
20

71. A process of determining the presence of a target sequence in a sample containing a nucleic acid of interest comprising the steps of the process of claim 4.

1/22




FIG.1




FIG.2

2/22




FIG.3




FIG.4

3/22





FIG. 5

SUBSTITUTE SHEET (RULE 26)


4/22

VERSION 6

PROBE 1




PROBE 2




VERSION 7

PROBE 1




PROBE 2




VERSION 8

PROBE 1




PROBE 2




VERSION 9

PROBE 1



PROBE 2

FIG. 5  
(CONTINUED)


SUBSTITUTE SHEET (RULE 26)




5/22

VERSION 10

PROBE 1




PROBE 2




VERSION 11

PROBE 1




PROBE 2




VERSION 12

PROBE 1



PROBE 2

FIG.5  
(CONTINUED)

6/22




FIG.6




FIG.7




FIG.8

7/22




FIG.9

8/22




FIG. 10




FIG. 11

10/22




 $G_1$  $G_2$  $G_3$ 

FIG.12

11/22






FIG.13

12/22





13/22




FIG.16




FIG.17

14/22




FIG.18




FIG.19

15/22





FIG.20

16/22





FIG.21


SUBSTITUTE SHEET (RULE 26)

17/22

# OPTION 1 WILD-TYPE NUCLEIC ACID SEQUENCE



## OPTION 2



## OPTION 3





FIG.22


SUBSTITUTE SHEET (RULE 26)

18/22


## OPTION 1 MUTANT NUCLEIC ACID SEQUENCE



## OPTION 2



## OPTION 3

FIG.22  
(CONTINUED)

19/22

## AMPLIFICATION PRODUCT






FIG.23

SUBSTITUTE SHEET (RULE 26)

20/22




FIG.24




FIG.25








FIG.27

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/06042

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b>   |  |  |
|--|--|--|
| IPC(6) : C12Q 1/68; C12P 19/34; C07H 21/02, 21/04  |  |  |
| US CL : Please See Extra Sheet.  |  |  |
| According to International Patent Classification (IPC) or to both national classification and IPC  |  |  |
| <b>B. FIELDS SEARCHED</b>  |  |  |
| Minimum documentation searched (classification system followed by classification symbols)  |  |  |
| U.S. : 435/6, 91.1, 91.2; 536/22.1, 23.1, 24.3, 24.31, 24.32, 24.33, 24.5  |  |  |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                    |  |  |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                     |  |  |
| Please See Extra Sheet.  |  |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>  |  |  |
| Category*  | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |
| Y  | WO 94/29485 A1 (IMCLONE SYSTEMS INCORPORATED) 22 December 1994, see entire document.   | 1-71   |
| Y  | US 5,185,243 A (E.F. ULLMAN ET AL) 09 February 1993, see entire document.  | 1-71   |
| Y  | EP 450 594 A2 (D. SEGEV) 09 October 1991, see entire document.   | 1-71   |
| Y  | MATTHEWS et al. Analytical strategies for the use of DNA probes. Analytical Biochemistry. 1988, Vol. 169, pages 1-25, see entire document.                         | 1-71   |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. |  |  |
| * "A"  | document defining the general state of the art which is not considered to be of particular relevance   | * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| * "E"  | earlier document published on or after the international filing date   | * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| * "L"  | document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| * "O"  | document referring to an oral disclosure, use, exhibition or other means   | * "Z" document member of the same patent family  |
| * "P"  | document published prior to the international filing date but later than the priority date claimed   |  |
| Date of the actual completion of the international search  |  | Date of mailing of the international search report   |
| 18 JULY 1996   |  | 14 AUG 1996  |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231                               |  | Authorized officer<br>JEFFREY FREDMAN  |
| Facsimile No. (703) 305-3230   |  | Telephone No. (703) 308-0196   |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/06042

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim N . |
|-----------|---|-----------------------|
| Y         | WU et al. The ligation amplification reaction (LAR) - Amplification of specific DNA sequences using sequential rounds of template-dependent ligation. Genomics. 1989, Vol. 5, pages 560-569, see entire document. | 1-71                  |
| Y         | Stratagene Catalog, 1994, page 113, see entire document.  | 62-67                 |
| Y, P      | US 5,437,977 A (SEGEV) 01 August 1995, see entire document.   | 1-71                  |
| A, P      | US 5,451,503 A (HOGAN ET AL) 19 September 1995, see entire document.  | 1-71                  |
| A         | US 5,359,100 A (URDEA ET AL) 25 October 1994, see entire document.  | 1-71                  |
| A, P      | US 5,427,929 A (RICHARDS ET AL) 27 June 1995, see entire document.  | 1-71                  |
| A, P      | US 5,424,413 A (HOGAN ET AL) 13 June 1995, see entire document.   | 1-71                  |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/06042

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/6, 91.1, 91.2; 536/22.1, 23.1, 24.3, 24.31, 24.32, 24.33, 24.5

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE BIOSIS CAPLUS WPIDS

search terms: hybrid?, anneal?, primer, probe, oligonucleotide, oligo, DNA, RNA, nucleic, block?, interfer?, protect?, ligat?, link?, bind?, join?, coupl?, amplif?, detect?, seq, pair

# KR SOURCEONE<sup>SM</sup>

DELIVERY VIA: EXPRESS

*For questions regarding this delivery, please contact Product Support at 800-334-2564 or fax us at 415-254-8123. Please have your DIALOG User Number and order number available.*

Source: KR SourceOne: EPO Patent Images

For:

NEXSTAR PHARMS INC  
ATTN: DIANE MCCLEARN CRUZ  
2860 WILDERNESS PL STE 200  
BOULDER CO 80301-5415

Subaccount: WOLFGANG PATENT  
Subject: PATENT REQUESTED BY WOLFGANG  
Estimated Cost: \$16.00  
Order Date: 97/04/30  
Order Number: RD424  
User Number: 130348  
Number of Pages: 129

\* Charges listed are for informational purposes only. Does not include applicable tax or telecommunications charges.

Copyrighted material reproduced with permission of copyright owner and further reproduction is prohibited or otherwise subject to restrictions. Patents are not copyrighted and may be freely reproduced.

**KR** KNIGHT-RIDDER  
INFORMATION

Knight-Ridder Information, Inc., Worldwide Headquarters  
2440 El Camino Real, Mountain View, CA 94040  
800-334-2564 or 415-254-8700